<?xml version="1.0" encoding="UTF-8"?>
<PAPER>

<BODY>
<DIV><P>
</P>
<P>[0001] RAPID ACTING AND PROLONGED ACTING
<ne type="CHEMICAL" id="WO2007041481.HC.substance-names.1" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">INSULIN</ne> PREPARATIONS Cross-Reference to Related Applications
This application claims priority to U.S.S.N. 60/721,698 filed in the U.S. Patent &amp; Trademark Office on September 29, 2005, by Solomon S. Steiner.
Background of the Invention
The present invention is generally in the field of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.2" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> formulations, and is specifically formulations of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.3" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> that are more rapid acting and/or have a more prolonged or enhanced period of activity.
When a healthy individual begins a meal, he or she experiences a natural spike of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.4" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> that is released by the pancreas, called the first phase <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.5" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> release. Currently available human <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.6" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="Human insulin" comment="" chebi-id="WO2007041481:962261" relevant="false">insulin</ne> preparations used by sufferers of diabetes do not replicate the natural first-phase <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.7" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> spike.
Instead, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.8" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> enters the bloodstream slowly, over a period of several hours. As a consequence, patients with diabetes have inadequate levels of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.9" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> present at the initiation of a meal and have too much <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.10" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> in their system between meals. Having too little <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.11" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> at the beginning of the meal causes abnormally high blood <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.81" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> levels (hyperglycemia) which are the cause of all the long term disabilities associated with diabetes, (such as retinopathies, neuropathies, nephropathies, bed sores &amp; amputations). Because they have too much <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.12" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> at the end of the meal, they are prone to a condition known as hypoglycemia, which is an abnormally low level of blood <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.82" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> between meals. Hypoglycemia can result in loss of mental acuity, confusion, increased heart rate, hunger, sweating, faintness and, at very low <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.83" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> levels, loss of consciousness, coma and even death.
While products that have recently been developed by several major pharmaceutical companies (such as Lilly, Novo-Nordisk, Aventis), at a cost of hundreds of millions of dollars, are a marked improvement over the preceding generation of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.13" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> products, they still are absorbed too slowly to mimic the natural initial <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.14" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> spike. In fall 2005, Pfizer/Nektar received an FDA advisory committee recommendation to approve their inhalable <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.15" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> product. Other inhalable <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.16" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> products, such as those of Lilly/Alkermes and Novo/Aridigm, are in the process of obtaining regulatory approval. Their pharmacokinetics is faster than injectable regular human <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.17" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="Human insulin" comment="" chebi-id="WO2007041481:962261" relevant="false">insulin</ne>, but not as fast as the rapid acting <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.18" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> analogs such as <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.164" epochem-id="EPOCHEM:NEW:SUBSTANCE:106" name="HUMALOG" comment="" chebi-id="WO2007041481:727145" relevant="false">Humalog</ne>(R).
These products could be vastly improved in their efficacy if they could be made to act more rapidly and mimic the natural initial <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.19" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> spike produced by non-diabetic individuals at the beginning of a meal. This is especially important with these pulmonary <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.243" epochem-id="EPOCHEM:NEW:SUBSTANCE:312" name="insulins" comment="" chebi-id="WO2007041481:619937" relevant="false">insulins</ne> as their intended use is to provide meal time <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.20" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> demand. Furthermore, if these pulmonary <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.21" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> formulations could be made to act fast enough to resemble the natural initial <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.22" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> spike produced by non-diabetic individuals at the beginning of a meal, then the liver would be able to respond to this rapid change in <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.23" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> level by shutting off the conversion of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.241" epochem-id="EPOCHEM:NEW:SUBSTANCE:311" name="glycogen" comment="" chebi-id="CHEBI:28087" relevant="false">glycogen</ne> to <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.84" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne>.
(The production of <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.85" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> by the liver by conversion from <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.242" epochem-id="EPOCHEM:NEW:SUBSTANCE:311" name="glycogen" comment="" chebi-id="CHEBI:28087" relevant="false">glycogen</ne> is called hepato- gluconeogenisis). The irony of the disease is that diabetics, who have insufficient <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.24" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> levels to adequately handle their <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.86" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne>, continue to make <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.87" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> in the liver while the concentration of blood <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.88" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> is increasing from the natural result of digestion. The liver responds only to the rate of change of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.25" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> level; not the absolute <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.26" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> level. By causing the blood <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.27" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> levels to rise rapidly and terminate hepato-gluconeogenisis, these improved pulmonary <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.28" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> formulations would allow diabetic patients to use less <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.29" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>, have sufficient <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.30" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> at the beginning of a meal and not suffer an excess of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.31" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> between meals. As a result they would have better gylceamic control and reduce the risk of both hyperglycemia and hypoglycemia.
It is therefore an object of the present invention to provide a method and reagents to yield a more rapidly acting <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.32" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>. It is a further object of the present invention to provide a longer acting <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.33" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>. Summary of the Invention
It has been discovered that by combining a <ne type="ONT" id="WO2007041481.HC.class-names.1" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.1" epochem-id="EPOCHEM:NEW:COMPOUND:1299" name="ethylenediaminetetraacetic acid" comment="" chebi-id="CHEBI:42191" relevant="true">ethylenediaminetetraacetic acid</ne> with an <ne type="ONT" id="WO2007041481.HC.class-names.37" epochem-id="EPOCHEM:NEW:CLASS:293" name="acidifier" comment="" chebi-id="WO2007041481:824461" relevant="false">acidifier</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.15" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>, that the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.34" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> is absorbed much more rapidly than in the absence of the <ne type="ONT" id="WO2007041481.HC.class-names.2" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> and <ne type="ONT" id="WO2007041481.HC.class-names.38" epochem-id="EPOCHEM:NEW:CLASS:293" name="acidifier" comment="" chebi-id="WO2007041481:824461" relevant="false">acidifier</ne>. By mixing this formulation with commercially available rapid acting <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.244" epochem-id="EPOCHEM:NEW:SUBSTANCE:312" name="insulins" comment="" chebi-id="WO2007041481:619937" relevant="false">insulins</ne>, it is possible to alter uptake and pharmacokinetic profiles. It has also been determined that by combining regular or intermediate lasting <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.35" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> with a <ne type="ONT" id="WO2007041481.HC.class-names.3" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> and <ne type="ONT" id="WO2007041481.HC.class-names.39" epochem-id="EPOCHEM:NEW:CLASS:293" name="acidifier" comment="" chebi-id="WO2007041481:824461" relevant="false">acidifier</ne>, with a long lasting' <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.36" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.153" epochem-id="EPOCHEM:NEW:SUBSTANCE:104" name="glargine" comment="" chebi-id="WO2007041481:668772" relevant="false">glargine</ne>, one can increase and/or prolong the bioavailability of the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.37" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> mixture. The formulations are suitable for administration by injection or mucosal delivery (oral, sublingual, buccal, vaginal, rectal, nasal or pulmonary), although subcutaneous injection is preferred. Methods for making pulmonary and solid formulations are described.
The examples demonstrate the enhanced rate of uptake obtained by providing a <ne type="ONT" id="WO2007041481.HC.class-names.4" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> and <ne type="ONT" id="WO2007041481.HC.class-names.95" epochem-id="EPOCHEM:NEW:CLASS:1072" name="acidifying agent" comment="" chebi-id="WO2007041481:823849" relevant="false">acidifying agent</ne> with rapid acting and long acting <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.245" epochem-id="EPOCHEM:NEW:SUBSTANCE:312" name="insulins" comment="" chebi-id="WO2007041481:619937" relevant="false">insulins</ne>. The examples also demonstrate that for the first four hours after administration, there is no significant difference between administering a long acting <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.38" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>, LANTUS, and <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.39" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.substance-names.40" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> containing <ne type="ONT" id="WO2007041481.HC.class-names.5" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> and <ne type="ONT" id="WO2007041481.HC.class-names.96" epochem-id="EPOCHEM:NEW:CLASS:1072" name="acidifying agent" comment="" chebi-id="WO2007041481:823849" relevant="false">acidifying agent</ne>, VIAJECT) mixed together or administered separately, however, after the first four hours and up to at least eight hours, there is a very large and significant difference with the mixture of VIAJECT and LANTUS having a much greater effect on lowering blood <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.89" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne>.
Brief Description of the Drawings
Figure 1 is a graph of a filter study demonstrating the decrease in apparent size of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.41" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> molecules (percent of less than 30,000 mw) in the presence of <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.42" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.16" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>.
Figure 2 is a graph of the effect of <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.43" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.17" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne> on apparent permeability of the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.42" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>.
Figure 3 is a graph of blood <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.90" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> levels (mg/dl plasma) over time before (baseline period), during a meal, and after the meal, in minutes, comparing separate and mixed administration of LANTUS (R) and VIAJECT(TM). Figure 4 is a graph of the blood <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.91" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> levels with baseline subtracted from blood <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.92" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> area under the curve (BG AUC) comparing separate and mixed administration of LANTUS(R) and VIAJECT(TM).
Detailed Description of the Invention I. Compositions
A. Drugs to be Administered
In the preferred embodiment, the active agent is <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.43" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> or an analog or derivative thereof. The <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.44" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> can be recombinant or purified.
In the preferred embodiment, the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.45" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> is recombinant human <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.46" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="Human insulin" comment="" chebi-id="WO2007041481:962261" relevant="false">insulin</ne>. The initial source of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.47" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> for clinical use in humans was from cow, horse, pig or fish pancreases. <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.48" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> from these sources is effective in humans as it is nearly identical to human <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.49" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="Human insulin" comment="" chebi-id="WO2007041481:962261" relevant="false">insulin</ne> (three <ne id="WO2007041481.HC.class-names.83" epochem-id="EPOCHEM:NEW:CLASS:972" name="amino acid" comment="" chebi-id="CHEBI:33708" relevant="false" type="CLASS">amino acid</ne> difference for bovine <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.50" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>, one <ne id="WO2007041481.HC.class-names.84" epochem-id="EPOCHEM:NEW:CLASS:972" name="amino acid" comment="" chebi-id="CHEBI:33708" relevant="false" type="CLASS">amino acid</ne> difference for porcine). <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.51" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> is a protein which has been very strongly conserved across evolutionary time. Differences in suitability of beef, pork, or fish <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.52" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> preparations for particular patients have been primarily the result of preparation purity and of allergic reactions to assorted non-<ne type="CHEMICAL" id="WO2007041481.HC.substance-names.53" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> substances remaining in those preparations. Purity has improved more or less steadily since the 1920s, but allergic reactions have continued though slowly reducing in severity. <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.54" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> production from animal pancreases was widespread for decades, but there are very few patients today relying on <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.55" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> from these sources.
Recombinant human <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.56" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="Human insulin" comment="" chebi-id="WO2007041481:962261" relevant="false">insulin</ne> is available from a number of sources. Human <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.57" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="Human insulin" comment="" chebi-id="WO2007041481:962261" relevant="false">insulin</ne> is now manufactured for widespread clinical use using genetic engineering techniques, which significantly reduces impurity reactionp roblems. Eli Lilly marketed the first such <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.58" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>, Humulin, in 1982.
The commonly used types of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.59" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> are:
Quick-acting, such as <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.60" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> lispro ~ begins to work within 5 to 15 minutes and is active for 3 to 4 hours. Short-acting, such as regular <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.61" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> ~ starts working within 30 minutes and is active about 5 to 8 hours. Intermediate-acting, such as NPH, or lente <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.62" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> ~ starts working in 1 to 3 hours and is active 16 to 24 hours.
Long-acting, such as ultralente <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.63" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> ~ starts working in 4 to 6 hours, and is active 24 to 28 hours, and <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.64" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.154" epochem-id="EPOCHEM:NEW:SUBSTANCE:104" name="glargine" comment="" chebi-id="WO2007041481:668772" relevant="false">glargine</ne> or <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.65" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> detemir - both start working within 1 to 2 hours and continue to be active, without peaks or dips, for about 24 hours.
A mixture of NPH and regular <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.66" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> - starts working in 30 minutes and is active 16 to 24 hours. There are several variations with different proportions of the mixed <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.246" epochem-id="EPOCHEM:NEW:SUBSTANCE:312" name="insulins" comment="" chebi-id="WO2007041481:619937" relevant="false">insulins</ne>. The dosage depends on the bioavailability and the disease or disorder to be treated, as well as the individual patient. <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.67" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> is generally included in a dosage range of 12 to 2000 IU per human dose. Thus if the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.68" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> has a bioavailability 5-25%, the actual systemic dose delivered to an individual ranges from 3 to 100 IU. For <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.69" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> with only 2.5 % bioavailability, an oral dose of 4,000 IU will deliver a 100 IU systemically available dose. For <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.70" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> with a much greater bioavailability, such as a 50% bioavailability, the delivery of a 3 IU systemically available dose requires an oral dose of 6 IU. Both natural and recombinant <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.247" epochem-id="EPOCHEM:NEW:SUBSTANCE:312" name="insulins" comment="" chebi-id="WO2007041481:619937" relevant="false">insulins</ne> are available. Human <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.71" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="Human insulin" comment="" chebi-id="WO2007041481:962261" relevant="false">insulin</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.128" epochem-id="EPOCHEM:NEW:SUBSTANCE:95" name="HUMALIN" comment="" chebi-id="WO2007041481:634619" relevant="false">HUMALIN</ne>(R) R, U 100, is available as a solution for injection from Eli Lilly and Company, single dose 0.1 IU/kg. <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.72" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> lispro, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.165" epochem-id="EPOCHEM:NEW:SUBSTANCE:106" name="HUMALOG" comment="" chebi-id="WO2007041481:727145" relevant="false">HUMALOG</ne>(R) R, is available as a solution for injection, from Eli Lilly and Company, single dose 0.1 IU/kg. <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.73" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.155" epochem-id="EPOCHEM:NEW:SUBSTANCE:104" name="glargine" comment="" chebi-id="WO2007041481:668772" relevant="false">glargine</ne>, LANTUS(R) R, U 100, is available from Sanofi- Aventis, as a solution for injection, 0.1 IU/kg
VIAJECT(TM), <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.74" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> solution including <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.44" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.18" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>, for injection 25 IU/ml prepared from recombinant human <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.75" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="Human insulin" comment="" chebi-id="WO2007041481:962261" relevant="false">insulin</ne>, is available from Biodel, Inc.,(pending FDA approval)
This technology is also useful with parathyroid hormone amino acids, 1-34, PTH, and analogs and derivatives thereof.
B. Solubilizing agents In the preferred embodiment, one or more solubilizing agents are included with the active agent to promote rapid dissolution in aqueous media. Suitable acids include <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.9" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.12" epochem-id="EPOCHEM:NEW:COMPOUND:963" name="ascorbic acid" comment="" chebi-id="CHEBI:22652" relevant="false">ascorbic acid</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.19" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>, and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.34" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>. For example, if the active agent is <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.76" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>, a preferred <ne type="ONT" id="WO2007041481.HC.class-names.26" epochem-id="EPOCHEM:NEW:CLASS:292" name="solubilizing agent" comment="" chebi-id="WO2007041481:514080" relevant="false">solubilizing agent</ne> is <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.20" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>. Results are best using <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.21" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne> as the solubilizer, although <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.13" epochem-id="EPOCHEM:NEW:COMPOUND:963" name="ascorbic acid" comment="" chebi-id="CHEBI:22652" relevant="false">ascorbic acid</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.10" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne> also yield substantial enhancement, while <ne type="FORMULA" id="WO2007041481.HC.formula-names.3" epochem-id="EPOCHEM:NEW:FORMULA:106" name="HCl" comment="" chebi-id="CHEBI:17883" relevant="false">HCl</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.100" epochem-id="EPOCHEM:COMPOUND:1226" name="sulfuric acid" comment="" chebi-id="CHEBI:26836" relevant="false">sulfuric acid</ne> yield poor enhancement. Other suitable solubilizing agents include wetting agents such as <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.259" epochem-id="EPOCHEM:NEW:SUBSTANCE:152" name="polysorbates" comment="" chebi-id="WO2007041481:981207" relevant="false">polysorbates</ne> and poloxamers, non-ionic and ionic <ne type="ONT" id="WO2007041481.HC.class-names.85" epochem-id="EPOCHEM:NEW:CLASS:960" name="surfactants" comment="" chebi-id="CHEBI:35195" relevant="false">surfactants</ne>, food acids and bases (e.g. <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.101" epochem-id="EPOCHEM:COMPOUND:8344" name="sodium bicarbonate" comment="" chebi-id="CHEBI:32139" relevant="false">sodium bicarbonate</ne>), and <ne id="WO2007041481.HC.class-names.92" epochem-id="EPOCHEM:NEW:CLASS:632" name="alcohols" comment="" chebi-id="CHEBI:30879" relevant="false" type="CLASS">alcohols</ne>, and <ne type="ONT" id="WO2007041481.HC.class-names.94" epochem-id="EPOCHEM:NEW:CLASS:1071" name="buffer salts" comment="" chebi-id="WO2007041481:318692" relevant="false">buffer salts</ne> for pH control.
C. <ne type="ONT" id="WO2007041481.HC.class-names.68" epochem-id="EPOCHEM:NEW:CLASS:33" name="chelators" comment="" chebi-id="CHEBI:38161" relevant="false">Chelators</ne> In the preferred embodiment, a metal <ne type="ONT" id="WO2007041481.HC.class-names.6" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> is mixed with the active agent or in a coating surrounding the active agent. The <ne type="ONT" id="WO2007041481.HC.class-names.7" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> may be ionic or non-ionic. Suitable <ne type="ONT" id="WO2007041481.HC.class-names.69" epochem-id="EPOCHEM:NEW:CLASS:33" name="chelators" comment="" chebi-id="CHEBI:38161" relevant="false">chelators</ne> include <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.2" epochem-id="EPOCHEM:NEW:COMPOUND:1299" name="ethylenediaminetetraacetic acid" comment="" chebi-id="CHEBI:42191" relevant="true">ethylenediaminetetraacetic acid</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.45" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne>), <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.22" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.5" epochem-id="EPOCHEM:NEW:COMPOUND:1300" name="dimercaprol" comment="" chebi-id="WO2007041481:771195" relevant="true">dimercaprol</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.61" epochem-id="EPOCHEM:NEW:COMPOUND:1304" name="BAL" comment="" chebi-id="WO2007041481:19869" relevant="false">BAL</ne>), <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.7" epochem-id="EPOCHEM:NEW:COMPOUND:1301" name="penicillamine" comment="" chebi-id="WO2007041481:759765" relevant="false">penicillamine</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.124" epochem-id="EPOCHEM:NEW:SUBSTANCE:39" name="alginic acid" comment="" chebi-id="WO2007041481:389621" relevant="false">alginic acid</ne>, chlorella, cilantro, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.226" epochem-id="EPOCHEM:NEW:COMPOUND:1997" name="alpha lipoic acid" comment="" chebi-id="WO2007041481:775873" relevant="false">alpha lipoic acid</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.36" epochem-id="EPOCHEM:NEW:COMPOUND:1302" name="Dimercaptosuccinic Acid" comment="" chebi-id="WO2007041481:192235" relevant="true">dimercaptosuccinic acid</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.65" epochem-id="EPOCHEM:NEW:COMPOUND:1306" name="DMSA" comment="" chebi-id="WO2007041481:112811" relevant="false">DMSA</ne>), <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.38" epochem-id="EPOCHEM:NEW:COMPOUND:1303" name="dimercaptopropane sulfonate" comment="" chebi-id="WO2007041481:77436" relevant="true">dimercaptopropane sulfonate</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.63" epochem-id="EPOCHEM:NEW:COMPOUND:1305" name="DMPS" comment="" chebi-id="CHEBI:888" relevant="false">DMPS</ne>), and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.40" epochem-id="EPOCHEM:COMPOUND:441" name="oxalic acid" comment="" chebi-id="CHEBI:16995" relevant="true">oxalic acid</ne>. In the preferred embodiment, the <ne type="ONT" id="WO2007041481.HC.class-names.8" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> is <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.46" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne>.
The <ne type="ONT" id="WO2007041481.HC.class-names.9" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> hydrogen bonds with the active agent, thereby masking the charge of the active agent and facilitating transmembrane transport of the active agent. For example, when the active agent is <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.77" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>, in addition to charge masking, it is believed that the <ne type="ONT" id="WO2007041481.HC.class-names.10" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> pulls the <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.102" epochem-id="EPOCHEM:COMPOUND:7669" name="zinc" comment="" chebi-id="CHEBI:27363" relevant="false">zinc</ne> away from the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.78" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>, thereby favoring the monomeric form of the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.79" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> over the hexameric form and facilitating absorption of the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.80" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> by the tissues surrounding the site of administration (e.g. mucosa, or fatty tissue). Optionally, the <ne type="ONT" id="WO2007041481.HC.class-names.11" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> and <ne type="ONT" id="WO2007041481.HC.class-names.27" epochem-id="EPOCHEM:NEW:CLASS:292" name="solubilizing agent" comment="" chebi-id="WO2007041481:514080" relevant="false">solubilizing agent</ne> are the same compound. Ions may be part of the active agent, added to the stabilizing agent, mixed with the <ne type="ONT" id="WO2007041481.HC.class-names.12" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne>, and/or included in the coating. Representative ions include <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.103" epochem-id="EPOCHEM:COMPOUND:7669" name="zinc" comment="" chebi-id="CHEBI:27363" relevant="false">zinc</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.106" epochem-id="EPOCHEM:COMPOUND:7090" name="calcium" comment="" chebi-id="CHEBI:22984" relevant="false">calcium</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.115" epochem-id="EPOCHEM:COMPOUND:7456" name="iron" comment="" chebi-id="CHEBI:18248" relevant="false">iron</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.116" epochem-id="EPOCHEM:COMPOUND:7452" name="manganese" comment="" chebi-id="CHEBI:18291" relevant="false">manganese</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.236" epochem-id="EPOCHEM:COMPOUND:7091" name="magnesium" comment="" chebi-id="CHEBI:25107" relevant="false">magnesium</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.242" epochem-id="EPOCHEM:NEW:COMPOUND:2026" name="aluminum" comment="" chebi-id="CHEBI:28984" relevant="false">aluminum</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.129" epochem-id="EPOCHEM:COMPOUND:7459" name="cobalt" comment="" chebi-id="CHEBI:27638" relevant="false">cobalt</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.130" epochem-id="EPOCHEM:COMPOUND:7465" name="copper" comment="" chebi-id="CHEBI:28694" relevant="false">copper</ne>, or any di-valent metal or transitional metal ion. <ne type="FORMULA" id="WO2007041481.HC.formula-names.5" epochem-id="EPOCHEM:NEW:FORMULA:107" name="Zn&lt;+2" comment="" chebi-id="WO2007041481:481248" relevant="false">Zn&lt;+2</ne>&gt; has a stronger binding preference for <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.47" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne> than <ne type="FORMULA" id="WO2007041481.HC.formula-names.6" epochem-id="EPOCHEM:NEW:FORMULA:108" name="Ca&lt;+2&gt;" comment="" chebi-id="WO2007041481:945054" relevant="false">Ca&lt;+2&gt;</ne>. Diluents
Diluents will typically be saline, physiological buffered saline, Ringer's or sterile <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.69" epochem-id="EPOCHEM:NEW:COMPOUND:9" name="Water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>. The diluent may contain the <ne type="ONT" id="WO2007041481.HC.class-names.76" epochem-id="EPOCHEM:NEW:CLASS:867" name="chelating agent" comment="" chebi-id="CHEBI:38161" relevant="false">chelating agent</ne> and/or the <ne type="ONT" id="WO2007041481.HC.class-names.28" epochem-id="EPOCHEM:NEW:CLASS:292" name="solubilizing agent" comment="" chebi-id="WO2007041481:514080" relevant="false">solubilizing agent</ne>. Preferred ingredients are those that are Generally Regarded As Safe
(GRAS) by the US FDA. II. Methods of Manufacture and Administration
The drugs can be prepared as powders or spray dried particles, and further formulated for administration by injection, pulmonary, or oral or sublingual routes of administration. Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania (1975), and Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N. Y. (1980). Proper formulation is dependent upon the route of administration chosen. The composition may be in the form of a dry powder containing the pharmaceutically active agent and one or more excipient(s). The active agents and excipients may be in the form of particles having the same or different sizes. In one embodiment, the excipient particles are larger than the particles of agent. This will allow the small particles of agent to coat the larger particle so that both particles are administered simultaneously.
Typically, the average particle diameter for the agent particles is less than or equal to one-tenth of the average particle diameter for the excipient particles. For sublingual delivery, the large particles generally have diameters greater than 8 [mu]m, preferably greater than 20 [mu]m. The average diameters for the large particles typically range from 8 [mu]m to 500 [mu]m, preferably from 50 [mu]m to 150 [mu]m. The small particles generally have a diameter ranging from 1 run to 9 [mu]m, preferably from 100 nm to 400 nm. For buccal and nasal administration, the particles generally have similar size ranges to those described from sublingual administration. For pulmonary administration, the large particles typically have an average diameter ranging from 1 [mu]m to 10 [mu]m, preferably from 2 [mu]m to 5 [mu]m; and the small particles typically have an average diameter ranging from 10 nm to 1 [mu]m.
If the particles of excipient have generally the same size, the average diameters will generally be greater than 8 [mu]m, preferably greater than 20 [mu]m, with typical size ranges from 8 [mu]m to 500 [mu]m, and preferably from 50 [mu]m to 150 [mu]m (for sublingual, buccal and nasal administration); and from 1 [mu]m to 10 [mu]m, preferably from 2 [mu]m to 5 [mu]m (for pulmonary administration).
Optionally, the particles are oppositely charged, so that the excipient particles contain one charge and the agent particles contain the opposite charge so that the particles are administered simultaneously. The particles may be charged by blowing them into a chamber formed of plastic surfaces, which impart charge to the particles. Two oppositely charged chambers may be used. The charged particles may be formed by using an acidic solution to make one of the particles, and a basic solution to form the other particles. Alternatively, charge can be transferred through ion discharge (e.g. using a staticizer or destaticizer). If the particles of agent and excipient are oppositely charged, they may have the same average diameter or different average diameters.
In one embodiment, the particles are formed by spraying a solution of drug through an atomizer, into a dryer which removes the solvent, then the particles are further dried in a lyophilizer. In another embodiment, the particles are formed by spraying a solution of drug into liquid <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.228" epochem-id="EPOCHEM:NEW:COMPOUND:749" name="nitrogen" comment="" chebi-id="CHEBI:25555" relevant="false">nitrogen</ne>, which instantly freezes the drug, the particles are then removed and dried. Drug powders can also be prepared using standard drug milling techniques.
A. Injection
In the most preferred embodiment, the formulation is in a form suitable for subcutaneous injection. For injection, the formulations are preferably administered subcutaneously as a liquid. In this embodiment, the formulation is formed by mixing a powdered active agent with a liquid diluent that contains a pharmaceutically acceptable liquid carrier and one or more solubilizing agents. In the preferred embodiment, the active agent is <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.81" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>, and the diluent contains saline, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.48" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.23" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>. Prior to administration the powder and diluent are mixed together to form an injectable composition. In the most preferred embodiment, the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.82" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> is provided as a dry powder and the <ne type="ONT" id="WO2007041481.HC.class-names.77" epochem-id="EPOCHEM:NEW:CLASS:867" name="chelating agent" comment="" chebi-id="CHEBI:38161" relevant="false">chelating agent</ne> and <ne type="ONT" id="WO2007041481.HC.class-names.97" epochem-id="EPOCHEM:NEW:CLASS:1072" name="acidifying agent" comment="" chebi-id="WO2007041481:823849" relevant="false">acidifying agent</ne> are provided as a sterile aqueous liquid in an amount suitable for dissolution of the dry powdered <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.83" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>. In a typical formulation, the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.84" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> is reconstituted to a dosage concentration of 0.1 IU/kg. B. Pulmonary Delivery
In a preferred embodiment for preparation of a pulmonary formulation, an aqueous solution containing one part recombinant human ("rH") <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.85" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>, two parts of a suitable <ne type="ONT" id="WO2007041481.HC.class-names.78" epochem-id="EPOCHEM:NEW:CLASS:867" name="chelating agent" comment="" chebi-id="CHEBI:38161" relevant="false">chelating agent</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.49" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne>, two parts of a suitable <ne id="WO2007041481.HC.class-names.102" epochem-id="EPOCHEM:NEW:CLASS:1073" name="acid" comment="" chebi-id="CHEBI:37527" relevant="false" type="CLASS">acid</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.24" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>, 5 parts of a suitable sugar and a small amount of a suitable <ne type="ONT" id="WO2007041481.HC.class-names.71" epochem-id="EPOCHEM:NEW:CLASS:800" name="surfactant" comment="" chebi-id="CHEBI:35195" relevant="false">surfactant</ne> is gently and thoroughly mixed to form a clear solution. The solution is sterile filtered through a 0.2 micron filter into a sterile, enclosed vessel.
Under sterile conditions, the solution is passed through an appropriately small orifice to make droplets between 0.1 and 10 microns. The solution can be forced under pressure through a nozzle with very small and uniform holes or sprayed out through an ultrasonic nebulizer into a large volume of liquid <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.229" epochem-id="EPOCHEM:NEW:COMPOUND:749" name="nitrogen" comment="" chebi-id="CHEBI:25555" relevant="false">nitrogen</ne> or some other suitable cryogenic liquid. The frozen liquid is then lyophilized to form a uniform dry powder for use in any of a number of dry powder inhalers. The combination of ingredients containing one part <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.86" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>, two parts of a suitable <ne type="ONT" id="WO2007041481.HC.class-names.79" epochem-id="EPOCHEM:NEW:CLASS:867" name="chelating agent" comment="" chebi-id="CHEBI:38161" relevant="false">chelating agent</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.50" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne>, two parts of a suitable <ne id="WO2007041481.HC.class-names.103" epochem-id="EPOCHEM:NEW:CLASS:1073" name="acid" comment="" chebi-id="CHEBI:37527" relevant="false" type="CLASS">acid</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.25" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>, with or without a small amount of a suitable <ne type="ONT" id="WO2007041481.HC.class-names.72" epochem-id="EPOCHEM:NEW:CLASS:800" name="surfactant" comment="" chebi-id="CHEBI:35195" relevant="false">surfactant</ne>, can be used to speed the rate of absorption and bioavailability of an <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.87" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> formulation, especially for pulmonary administration.
The combination of ingredients containing one part <ne id="WO2007041481.HC.class-names.113" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> or protein, two parts of a suitable <ne type="ONT" id="WO2007041481.HC.class-names.80" epochem-id="EPOCHEM:NEW:CLASS:867" name="chelating agent" comment="" chebi-id="CHEBI:38161" relevant="false">chelating agent</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.51" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne>, two parts of a suitable <ne id="WO2007041481.HC.class-names.104" epochem-id="EPOCHEM:NEW:CLASS:1073" name="acid" comment="" chebi-id="CHEBI:37527" relevant="false" type="CLASS">acid</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.26" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>, and with or without a small amount of a suitable <ne type="ONT" id="WO2007041481.HC.class-names.73" epochem-id="EPOCHEM:NEW:CLASS:800" name="surfactant" comment="" chebi-id="CHEBI:35195" relevant="false">surfactant</ne> can also be used to speed the rate of absorption and bioavailability Preferred particle or powder sizes are between 1 and 3 microns, although smaller sizes may be used, from nanometers to 2 microns, or larger sizes, from three to five microns, if the particles are porous or otherwise very light. The particles may be administered using any of a number of different applicators. Suitable methods for manufacture and administration are described in the following U.S. patent Nos. 6,592,904, 6,518,239, 6,423,344, 6,294,204, 6,051,256 and 5,997,848 to Inhale (nowNektar); and U.S. Patent Nos.: 5,985,309, RE37,053, 6,254,854, 6,436,443, 6,447,753, 6,503,480, and 6,635,283 to Edwards, et al. (MIT, AIR). C. Mucosal Delivery
The mixtures may also be formulated for mucosal delivery, such as oral, nasal, buccal, vaginal, rectal or sublingual delivery. Suitable dosage forms include powders, films, wafers, lozenges, capsules, and tablets. In one preferred embodiment, the formulation is a sublingual solid formulation that contains an active agent, and at least one <ne type="ONT" id="WO2007041481.HC.class-names.29" epochem-id="EPOCHEM:NEW:CLASS:292" name="solubilizing agent" comment="" chebi-id="WO2007041481:514080" relevant="false">solubilizing agent</ne>, along with other standard excipients, such as <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.178" epochem-id="EPOCHEM:NEW:SUBSTANCE:111" name="poly(vinyl alcohol)" comment="" chebi-id="CHEBI:17246" relevant="false">poly(vinyl alcohol)</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.131" epochem-id="EPOCHEM:NEW:COMPOUND:98" name="glycerin" comment="" chebi-id="CHEBI:17754" relevant="false">glycerin</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.159" epochem-id="EPOCHEM:NEW:SUBSTANCE:75" name="carboxymethyl cellulose" comment="" chebi-id="WO2007041481:984331" relevant="false">carboxymethyl cellulose</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.substance-names.263" epochem-id="EPOCHEM:NEW:SUBSTANCE:315" name="CMC" comment="" chebi-id="WO2007041481:352358" relevant="false">CMC</ne>), and optionally <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.179" epochem-id="EPOCHEM:NEW:SUBSTANCE:112" name="poly(ethylene glycol)" comment="" chebi-id="WO2007041481:17366" relevant="false">poly(ethylene glycol)</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.70" epochem-id="EPOCHEM:NEW:COMPOUND:9" name="Water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>. The sublingual composition may be in the form of a dry powder, monolayer, bilayer, or trilayer film, a lyophilized wafer, lozenge, capsule, or a tablet. In addition to the excipients discussed above, these formulations may include one or more of the following.
Diluents and Fillers
Diluents, also referred to herein as fillers, are typically necessary to increase the bulk of a solid dosage form so that a practical size is provided for compression of tablets or formation of beads and granules. Suitable fillers include, but are not limited to, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.245" epochem-id="EPOCHEM:NEW:COMPOUND:2086" name="dicalcium phosphate dihydrate" comment="" chebi-id="WO2007041481:15421" relevant="false">dicalcium phosphate dihydrate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.107" epochem-id="EPOCHEM:COMPOUND:7090" name="calcium" comment="" chebi-id="CHEBI:22984" relevant="false">calcium</ne> <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.182" epochem-id="EPOCHEM:COMPOUND:1225" name="sulfate" comment="" chebi-id="CHEBI:16189" relevant="false">sulfate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.152" epochem-id="EPOCHEM:COMPOUND:2313" name="lactose" comment="" chebi-id="CHEBI:17716" relevant="false">lactose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.73" epochem-id="EPOCHEM:COMPOUND:1888" name="sucrose" comment="" chebi-id="CHEBI:17992" relevant="false">sucrose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.244" epochem-id="EPOCHEM:COMPOUND:2429" name="mannitol" comment="" chebi-id="CHEBI:29864" relevant="false">mannitol</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.154" epochem-id="EPOCHEM:NEW:COMPOUND:990" name="sorbitol" comment="" chebi-id="CHEBI:30911" relevant="false">sorbitol</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.208" epochem-id="EPOCHEM:NEW:SUBSTANCE:79" name="cellulose" comment="" chebi-id="WO2007041481:524699" relevant="false">cellulose</ne>, microcrystalline <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.209" epochem-id="EPOCHEM:NEW:SUBSTANCE:79" name="cellulose" comment="" chebi-id="WO2007041481:524699" relevant="false">cellulose</ne>, powdered <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.210" epochem-id="EPOCHEM:NEW:SUBSTANCE:79" name="cellulose" comment="" chebi-id="WO2007041481:524699" relevant="false">cellulose</ne>, kaolin, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.137" epochem-id="EPOCHEM:COMPOUND:6837" name="sodium chloride" comment="" chebi-id="CHEBI:26710" relevant="false">sodium chloride</ne>, dry <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.223" epochem-id="EPOCHEM:NEW:SUBSTANCE:127" name="starch" comment="" chebi-id="CHEBI:28017" relevant="false">starch</ne>, hydrolyzed <ne id="WO2007041481.HC.class-names.120" epochem-id="EPOCHEM:NEW:CLASS:1078" name="starches" comment="" chebi-id="WO2007041481:326511" relevant="false" type="CLASS">starches</ne>, pregelatinized <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.224" epochem-id="EPOCHEM:NEW:SUBSTANCE:127" name="starch" comment="" chebi-id="CHEBI:28017" relevant="false">starch</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.230" epochem-id="EPOCHEM:NEW:COMPOUND:1998" name="silicone dioxide" comment="silicon dioxide" chebi-id="CHEBI:30563" relevant="false">silicone dioxide</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.231" epochem-id="EPOCHEM:NEW:COMPOUND:1999" name="titanium oxide" comment="" chebi-id="CHEBI:32234" relevant="false">titanium oxide</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.236" epochem-id="EPOCHEM:NEW:SUBSTANCE:247" name="magnesium aluminum silicate" comment="" chebi-id="WO2007041481:843440" relevant="false">magnesium aluminum silicate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.161" epochem-id="EPOCHEM:COMPOUND:6668" name="calcium carbonate" comment="" chebi-id="CHEBI:3311" relevant="false">calcium carbonate</ne>, compressible sugar, sugar spheres, powdered (confectioner's) sugar, dextrates, dextrin, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.150" epochem-id="EPOCHEM:NEW:COMPOUND:831" name="dextrose" comment="" chebi-id="WO2007041481:343150" relevant="false">dextrose</ne>, dibasic <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.246" epochem-id="EPOCHEM:NEW:COMPOUND:2087" name="calcium phosphate dehydrate" comment="" chebi-id="WO2007041481:654435" relevant="false">calcium phosphate dehydrate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.166" epochem-id="EPOCHEM:NEW:COMPOUND:1030" name="glyceryl palmitostearate" comment="" chebi-id="WO2007041481:646799" relevant="false">glyceryl palmitostearate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.247" epochem-id="EPOCHEM:COMPOUND:6670" name="magnesium carbonate" comment="" chebi-id="CHEBI:31793" relevant="false">magnesium carbonate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.248" epochem-id="EPOCHEM:NEW:COMPOUND:1784" name="magnesium oxide" comment="" chebi-id="CHEBI:31794" relevant="false">magnesium oxide</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.78" epochem-id="EPOCHEM:NEW:COMPOUND:1310" name="maltodextrin" comment="" chebi-id="WO2007041481:45063" relevant="false">maltodextrin</ne>, <ne id="WO2007041481.HC.class-names.40" epochem-id="EPOCHEM:NEW:CLASS:294" name="polymethacrylates" comment="" chebi-id="WO2007041481:620606" relevant="true" type="CLASS">polymethacrylates</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.249" epochem-id="EPOCHEM:COMPOUND:6839" name="potassium chloride" comment="" chebi-id="CHEBI:32588" relevant="false">potassium chloride</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.250" epochem-id="EPOCHEM:NEW:SUBSTANCE:313" name="talc" comment="" chebi-id="WO2007041481:714483" relevant="false">talc</ne>, and tribasic <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.251" epochem-id="EPOCHEM:NEW:COMPOUND:373" name="calcium phosphate" comment="" chebi-id="CHEBI:9679" relevant="false">calcium phosphate</ne>.
Binders Binders are used to impart cohesive qualities to a solid dosage formulation, and thus ensure that a tablet, bead or granule remains intact after the formation of the dosage forms.
Suitable binder materials include, but are not limited to, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.225" epochem-id="EPOCHEM:NEW:SUBSTANCE:127" name="starch" comment="" chebi-id="CHEBI:28017" relevant="false">starch</ne>, pregelatinized <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.226" epochem-id="EPOCHEM:NEW:SUBSTANCE:127" name="starch" comment="" chebi-id="CHEBI:28017" relevant="false">starch</ne>, gelatin, <ne id="WO2007041481.HC.class-names.74" epochem-id="EPOCHEM:NEW:CLASS:17" name="sugars" comment="" chebi-id="WO2007041481:254249" relevant="false" type="CLASS">sugars</ne> (including <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.74" epochem-id="EPOCHEM:COMPOUND:1888" name="sucrose" comment="" chebi-id="CHEBI:17992" relevant="false">sucrose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.93" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.151" epochem-id="EPOCHEM:NEW:COMPOUND:831" name="dextrose" comment="" chebi-id="WO2007041481:343150" relevant="false">dextrose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.153" epochem-id="EPOCHEM:COMPOUND:2313" name="lactose" comment="" chebi-id="CHEBI:17716" relevant="false">lactose</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.155" epochem-id="EPOCHEM:NEW:COMPOUND:990" name="sorbitol" comment="" chebi-id="CHEBI:30911" relevant="false">sorbitol</ne>), dextrin, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.79" epochem-id="EPOCHEM:NEW:COMPOUND:1310" name="maltodextrin" comment="" chebi-id="WO2007041481:45063" relevant="false">maltodextrin</ne>, zein, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.180" epochem-id="EPOCHEM:NEW:SUBSTANCE:2" name="polyethylene glycol" comment="" chebi-id="CHEBI:46793" relevant="false">polyethylene glycol</ne>, waxes, natural and synthetic gums such as acacia, guar gum, tragacanth, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.186" epochem-id="EPOCHEM:NEW:SUBSTANCE:12" name="alginate" comment="" chebi-id="WO2007041481:806723" relevant="false">alginate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.175" epochem-id="EPOCHEM:NEW:SUBSTANCE:61" name="sodium alginate" comment="" chebi-id="WO2007041481:110650" relevant="false">sodium alginate</ne>, <ne id="WO2007041481.HC.class-names.114" epochem-id="EPOCHEM:NEW:CLASS:1074" name="celluloses" comment="" chebi-id="WO2007041481:975805" relevant="false" type="CLASS">celluloses</ne>, including <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.182" epochem-id="EPOCHEM:NEW:SUBSTANCE:58" name="hydroxypropylmethylcellulose" comment="" chebi-id="WO2007041481:165340" relevant="false">hydroxypropylmethylcellulose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.142" epochem-id="EPOCHEM:NEW:SUBSTANCE:100" name="carboxymethylcellulose sodium" comment="" chebi-id="WO2007041481:710841" relevant="false">carboxymethylcellulose sodium</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.183" epochem-id="EPOCHEM:NEW:SUBSTANCE:81" name="hydroxypropylcellulose" comment="" chebi-id="WO2007041481:930292" relevant="false">hydroxypropylcellulose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.184" epochem-id="EPOCHEM:NEW:SUBSTANCE:113" name="hydroxylethylcellulose" comment="" chebi-id="WO2007041481:375906" relevant="false">hydroxylethylcellulose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.139" epochem-id="EPOCHEM:NEW:SUBSTANCE:98" name="ethylcellulose" comment="" chebi-id="WO2007041481:335383" relevant="false">ethylcellulose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.185" epochem-id="EPOCHEM:NEW:SUBSTANCE:114" name="methyl cellulose" comment="" chebi-id="WO2007041481:949788" relevant="false">methyl cellulose</ne>, and veegum, hydrogenated vegetable oil, Type I, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.156" epochem-id="EPOCHEM:NEW:COMPOUND:1319" name="magnesium alumninum silicate" comment="" chebi-id="WO2007041481:175190" relevant="false">magnesium alumninum silicate</ne>, and synthetic <ne id="WO2007041481.HC.class-names.122" epochem-id="EPOCHEM:NEW:CLASS:1079" name="polymers" comment="" chebi-id="CHEBI:33839" relevant="false" type="CLASS">polymers</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.252" epochem-id="EPOCHEM:COMPOUND:732" name="acrylic acid" comment="" chebi-id="CHEBI:18308" relevant="false">acrylic acid</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.157" epochem-id="EPOCHEM:COMPOUND:734" name="methacrylic acid" comment="" chebi-id="CHEBI:25219" relevant="false">methacrylic acid</ne> copolymers, carbomer, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.158" epochem-id="EPOCHEM:COMPOUND:734" name="methacrylic acid" comment="" chebi-id="CHEBI:25219" relevant="false">methacrylic acid</ne> copolymers, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.159" epochem-id="EPOCHEM:NEW:COMPOUND:1320" name="methyl methacrylate" comment="" chebi-id="WO2007041481:475032" relevant="false">methyl methacrylate</ne> copolymers, <ne id="WO2007041481.HC.class-names.115" epochem-id="EPOCHEM:NEW:CLASS:1075" name="aminoalkyl methacrylate" comment="" chebi-id="WO2007041481:567763" relevant="false" type="CLASS">aminoalkyl methacrylate</ne> copolymers, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.233" epochem-id="EPOCHEM:NEW:SUBSTANCE:245" name="polyacrylic acid" comment="" chebi-id="WO2007041481:4068" relevant="false">polyacrylic acid</ne>/<ne type="CHEMICAL" id="WO2007041481.HC.substance-names.234" epochem-id="EPOCHEM:NEW:SUBSTANCE:246" name="polymethacrylicacid" comment="" chebi-id="WO2007041481:751836" relevant="false">polymethacrylic acid</ne>, and <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.235" epochem-id="EPOCHEM:NEW:SUBSTANCE:71" name="polyvinylpyrrolidone" comment="" chebi-id="WO2007041481:431885" relevant="false">polyvinylpyrrolidone</ne>. Lubricants Lubricants are used to facilitate tablet manufacture. Examples of suitable lubricants include, but are not limited to, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.171" epochem-id="EPOCHEM:NEW:COMPOUND:85" name="magnesium stearate" comment="" chebi-id="CHEBI:9254" relevant="false">magnesium stearate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.170" epochem-id="EPOCHEM:NEW:COMPOUND:424" name="calcium stearate" comment="" chebi-id="WO2007041481:473037" relevant="false">calcium stearate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.169" epochem-id="EPOCHEM:COMPOUND:693" name="stearic acid" comment="" chebi-id="CHEBI:28842" relevant="false">stearic acid</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.168" epochem-id="EPOCHEM:NEW:COMPOUND:1029" name="glyceryl behenate" comment="" chebi-id="WO2007041481:894658" relevant="false">glyceryl behenate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.146" epochem-id="EPOCHEM:NEW:COMPOUND:1028" name="glyceryl monostearate" comment="" chebi-id="WO2007041481:311712" relevant="false">glyceryl monostearate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.167" epochem-id="EPOCHEM:NEW:COMPOUND:1030" name="glyceryl palmitostearate" comment="" chebi-id="WO2007041481:646799" relevant="false">glyceryl palmitostearate</ne>, hydrogenated castor oil, hydrogenated vegetable oil, type I, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.165" epochem-id="EPOCHEM:NEW:COMPOUND:1322" name="sodium benzoate" comment="" chebi-id="WO2007041481:701276" relevant="false">sodium benzoate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.163" epochem-id="EPOCHEM:NEW:COMPOUND:425" name="sodium lauryl sulfate" comment="" chebi-id="CHEBI:8984" relevant="false">sodium lauryl sulfate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.162" epochem-id="EPOCHEM:NEW:COMPOUND:1321" name="sodium stearyl fumarate" comment="" chebi-id="WO2007041481:925852" relevant="false">sodium stearyl fumarate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.181" epochem-id="EPOCHEM:NEW:SUBSTANCE:2" name="polyethylene glycol" comment="" chebi-id="CHEBI:46793" relevant="false">polyethylene glycol</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.251" epochem-id="EPOCHEM:NEW:SUBSTANCE:313" name="talc" comment="" chebi-id="WO2007041481:714483" relevant="false">talc</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.172" epochem-id="EPOCHEM:NEW:COMPOUND:268" name="zinc stearate" comment="" chebi-id="WO2007041481:657510" relevant="false">zinc stearate</ne>, and mineral oil and light mineral oil.
Disintegrants
Disintegrants are used to facilitate dosage form disintegration or "breakup" after administration, and generally include, but are not limited to, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.227" epochem-id="EPOCHEM:NEW:SUBSTANCE:127" name="starch" comment="" chebi-id="CHEBI:28017" relevant="false">starch</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.192" epochem-id="EPOCHEM:NEW:SUBSTANCE:115" name="sodium starch glycolate" comment="" chebi-id="WO2007041481:940793" relevant="false">sodium starch glycolate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.194" epochem-id="EPOCHEM:NEW:SUBSTANCE:116" name="sodium carboxymethyl starch" comment="" chebi-id="WO2007041481:320890" relevant="false">sodium carboxymethyl starch</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.135" epochem-id="EPOCHEM:NEW:SUBSTANCE:56" name="methylcellulose" comment="" chebi-id="WO2007041481:399316" relevant="false">methylcellulose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.112" epochem-id="EPOCHEM:COMPOUND:7090" name="calcium" comment="" chebi-id="CHEBI:22984" relevant="false">calcium</ne> <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.196" epochem-id="EPOCHEM:NEW:SUBSTANCE:87" name="carboxymethylcellulose" comment="" chebi-id="WO2007041481:784292" relevant="false">carboxymethylcellulose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.202" epochem-id="EPOCHEM:NEW:SUBSTANCE:62" name="sodium carboxymethylcellulose" comment="" chebi-id="WO2007041481:587833" relevant="false">sodium carboxymethylcellulose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.169" epochem-id="EPOCHEM:NEW:SUBSTANCE:32" name="hydroxypropyl cellulose" comment="" chebi-id="WO2007041481:394470" relevant="false">hydroxypropyl cellulose</ne>, microcrystalline <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.213" epochem-id="EPOCHEM:NEW:SUBSTANCE:79" name="cellulose" comment="" chebi-id="WO2007041481:524699" relevant="false">cellulose</ne>, colloidal <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.253" epochem-id="EPOCHEM:NEW:SUBSTANCE:169" name="silicon dioxide" comment="" chebi-id="CHEBI:30563" relevant="false">silicon dioxide</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.203" epochem-id="EPOCHEM:NEW:SUBSTANCE:117" name="croscarmellose sodium" comment="" chebi-id="WO2007041481:41457" relevant="false">croscarmellose sodium</ne>, pregelatinized <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.230" epochem-id="EPOCHEM:NEW:SUBSTANCE:127" name="starch" comment="" chebi-id="CHEBI:28017" relevant="false">starch</ne>, clays, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.214" epochem-id="EPOCHEM:NEW:SUBSTANCE:79" name="cellulose" comment="" chebi-id="WO2007041481:524699" relevant="false">cellulose</ne>, powdered <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.215" epochem-id="EPOCHEM:NEW:SUBSTANCE:79" name="cellulose" comment="" chebi-id="WO2007041481:524699" relevant="false">cellulose</ne>, pregelatinized <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.231" epochem-id="EPOCHEM:NEW:SUBSTANCE:127" name="starch" comment="" chebi-id="CHEBI:28017" relevant="false">starch</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.193" epochem-id="EPOCHEM:NEW:SUBSTANCE:115" name="sodium starch glycolate" comment="" chebi-id="WO2007041481:940793" relevant="false">sodium starch glycolate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.204" epochem-id="EPOCHEM:NEW:SUBSTANCE:118" name="sodium aginate" comment="" chebi-id="WO2007041481:721217" relevant="false">sodium aginate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.125" epochem-id="EPOCHEM:NEW:SUBSTANCE:39" name="alginic acid" comment="" chebi-id="WO2007041481:389621" relevant="false">alginic acid</ne>, guar gum, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.237" epochem-id="EPOCHEM:NEW:SUBSTANCE:247" name="magnesium aluminum silicate" comment="" chebi-id="WO2007041481:843440" relevant="false">magnesium aluminum silicate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.205" epochem-id="EPOCHEM:NEW:SUBSTANCE:119" name="polacrilin potassium" comment="http://www.rohmhaas.com/ionexchange/Pharmaceuticals/Formulations_doc/english/Irp88.PDF" chebi-id="WO2007041481:67416" relevant="false">polacrilin potassium</ne>, and cross linked <ne id="WO2007041481.HC.class-names.123" epochem-id="EPOCHEM:NEW:CLASS:1079" name="polymers" comment="" chebi-id="CHEBI:33839" relevant="false" type="CLASS">polymers</ne>, such as cross-linked PVP, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.206" epochem-id="EPOCHEM:NEW:SUBSTANCE:86" name="crospovidone" comment="" chebi-id="WO2007041481:781792" relevant="false">crospovidone</ne> (POLYPLASDONE(R) XL from GAF Chemical Corp). Stabilizers
Stabilizers are used to inhibit or retard drug decomposition reactions which include, by way of example, oxidative reactions. A number of stabilizers may be used.
Suitable stabilizers include <ne id="WO2007041481.HC.class-names.56" epochem-id="EPOCHEM:NEW:CLASS:57" name="polysaccharides" comment="" chebi-id="CHEBI:18154" relevant="false" type="CLASS">polysaccharides</ne>, such as <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.216" epochem-id="EPOCHEM:NEW:SUBSTANCE:79" name="cellulose" comment="" chebi-id="WO2007041481:524699" relevant="false">cellulose</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.217" epochem-id="EPOCHEM:NEW:SUBSTANCE:79" name="cellulose" comment="" chebi-id="WO2007041481:524699" relevant="false">cellulose</ne> derivatives, and simple <ne id="WO2007041481.HC.class-names.93" epochem-id="EPOCHEM:NEW:CLASS:632" name="alcohols" comment="" chebi-id="CHEBI:30879" relevant="false" type="CLASS">alcohols</ne>, such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.134" epochem-id="EPOCHEM:COMPOUND:1821" name="glycerol" comment="" chebi-id="CHEBI:17754" relevant="false">glycerol</ne>; <ne type="ONT" id="WO2007041481.HC.class-names.60" epochem-id="EPOCHEM:NEW:CLASS:303" name="bacteriostatic agents" comment="" chebi-id="WO2007041481:637969" relevant="false">bacteriostatic agents</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.173" epochem-id="EPOCHEM:COMPOUND:4254" name="phenol" comment="" chebi-id="CHEBI:15882" relevant="false">phenol</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.174" epochem-id="EPOCHEM:COMPOUND:3812" name="m-cresol" comment="" chebi-id="CHEBI:17231" relevant="false">m-cresol</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.175" epochem-id="EPOCHEM:NEW:COMPOUND:248" name="methylparaben" comment="" chebi-id="WO2007041481:587441" relevant="false">methylparaben</ne>; <ne type="ONT" id="WO2007041481.HC.class-names.58" epochem-id="EPOCHEM:NEW:CLASS:18" name="isotonic agents" comment="" chebi-id="WO2007041481:439850" relevant="false">isotonic agents</ne>, such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.138" epochem-id="EPOCHEM:COMPOUND:6837" name="sodium chloride" comment="" chebi-id="CHEBI:26710" relevant="false">sodium chloride</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.135" epochem-id="EPOCHEM:COMPOUND:1821" name="glycerol" comment="" chebi-id="CHEBI:17754" relevant="false">glycerol</ne>, and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.94" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne>; <ne id="WO2007041481.HC.class-names.42" epochem-id="EPOCHEM:NEW:CLASS:70" name="lecithins" comment="" chebi-id="CHEBI:16110" relevant="false" type="CLASS">lecithins</ne>, such as example natural <ne id="WO2007041481.HC.class-names.43" epochem-id="EPOCHEM:NEW:CLASS:70" name="lecithins" comment="" chebi-id="CHEBI:16110" relevant="false" type="CLASS">lecithins</ne> (e.g. egg yolk lecithin or soya bean lecithin) and synthetic or semisynthetic <ne id="WO2007041481.HC.class-names.44" epochem-id="EPOCHEM:NEW:CLASS:70" name="lecithins" comment="" chebi-id="CHEBI:16110" relevant="false" type="CLASS">lecithins</ne> (e.g. <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.139" epochem-id="EPOCHEM:NEW:COMPOUND:1311" name="dimyristoylphosphatidylcholine" comment="" chebi-id="CHEBI:23819" relevant="false">dimyristoylphosphatidylcholine</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.140" epochem-id="EPOCHEM:NEW:COMPOUND:1312" name="dipalmitoylphosphatidylcholine" comment="" chebi-id="WO2007041481:858760" relevant="false">dipalmitoylphosphatidylcholine</ne> or <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.141" epochem-id="EPOCHEM:NEW:COMPOUND:1313" name="distearoyl-phosphatidylcholine" comment="" chebi-id="WO2007041481:781661" relevant="false">distearoyl-phosphatidylcholine</ne> ; <ne id="WO2007041481.HC.class-names.46" epochem-id="EPOCHEM:NEW:CLASS:295" name="phosphatidic acids" comment="" chebi-id="CHEBI:16337" relevant="true" type="CLASS">phosphatidic acids</ne>; <ne id="WO2007041481.HC.class-names.47" epochem-id="EPOCHEM:NEW:CLASS:296" name="phosphatidylethanolamines" comment="" chebi-id="CHEBI:16038" relevant="false" type="CLASS">phosphatidylethanolamines</ne>; <ne id="WO2007041481.HC.class-names.48" epochem-id="EPOCHEM:NEW:CLASS:297" name="phosphatidylserines" comment="" chebi-id="WO2007041481:585785" relevant="false" type="CLASS">phosphatidylserines</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.142" epochem-id="EPOCHEM:NEW:COMPOUND:1314" name="distearoyl-phosphatidylserine" comment="" chebi-id="WO2007041481:557170" relevant="false">distearoyl-phosphatidylserine</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.143" epochem-id="EPOCHEM:NEW:COMPOUND:1315" name="dipalmitoylphosphatidylserine" comment="" chebi-id="WO2007041481:46234" relevant="false">dipalmitoylphosphatidylserine</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.144" epochem-id="EPOCHEM:NEW:COMPOUND:1316" name="diarachidoylphospahtidylserine" comment="" chebi-id="WO2007041481:696372" relevant="false">diarachidoylphospahtidylserine</ne>; <ne id="WO2007041481.HC.class-names.49" epochem-id="EPOCHEM:NEW:CLASS:298" name="phosphatidylglycerols" comment="" chebi-id="CHEBI:17517" relevant="true" type="CLASS">phosphatidylglycerols</ne>; <ne id="WO2007041481.HC.class-names.50" epochem-id="EPOCHEM:NEW:CLASS:299" name="phosphatidylinositols" comment="" chebi-id="CHEBI:28874" relevant="false" type="CLASS">phosphatidylinositols</ne>; <ne id="WO2007041481.HC.class-names.51" epochem-id="EPOCHEM:NEW:CLASS:300" name="cardiolipins" comment="" chebi-id="CHEBI:28494" relevant="false" type="CLASS">cardiolipins</ne>; <ne id="WO2007041481.HC.class-names.52" epochem-id="EPOCHEM:NEW:CLASS:301" name="sphingomyelins" comment="" chebi-id="CHEBI:17636" relevant="false" type="CLASS">sphingomyelins</ne>; and <ne type="ONT" id="WO2007041481.HC.class-names.53" epochem-id="EPOCHEM:NEW:CLASS:302" name="synthetic detergents" comment="" chebi-id="WO2007041481:151565" relevant="false">synthetic detergents</ne>, such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.145" epochem-id="EPOCHEM:NEW:COMPOUND:1317" name="diosctanoylphosphatidyl choline" comment="" chebi-id="WO2007041481:387092" relevant="false">diosctanoylphosphatidyl choline</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.167" epochem-id="EPOCHEM:NEW:SUBSTANCE:107" name="polyethylene- polypropylene" comment="" chebi-id="WO2007041481:651258" relevant="false">polyethylene- polypropylene</ne> glycol).
Other suitable stablizers include acacia, albumin, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.126" epochem-id="EPOCHEM:NEW:SUBSTANCE:39" name="alginic acid" comment="" chebi-id="WO2007041481:389621" relevant="false">alginic acid</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.168" epochem-id="EPOCHEM:NEW:SUBSTANCE:108" name="bentonite" comment="" chebi-id="WO2007041481:333500" relevant="false">bentonite</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.177" epochem-id="EPOCHEM:NEW:SUBSTANCE:110" name="carboxymethylcellulose calcium" comment="" chebi-id="WO2007041481:129462" relevant="false">carboxymethylcellulose calcium</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.143" epochem-id="EPOCHEM:NEW:SUBSTANCE:100" name="carboxymethylcellulose sodium" comment="" chebi-id="WO2007041481:710841" relevant="false">carboxymethylcellulose sodium</ne>, <ne id="WO2007041481.HC.class-names.55" epochem-id="EPOCHEM:NEW:CLASS:191" name="cyclodextrins" comment="" chebi-id="CHEBI:23456" relevant="true" type="CLASS">cyclodextrins</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.147" epochem-id="EPOCHEM:NEW:COMPOUND:1028" name="glyceryl monostearate" comment="" chebi-id="WO2007041481:311712" relevant="false">glyceryl monostearate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.170" epochem-id="EPOCHEM:NEW:SUBSTANCE:32" name="hydroxypropyl cellulose" comment="" chebi-id="WO2007041481:394470" relevant="false">hydroxypropyl cellulose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.132" epochem-id="EPOCHEM:NEW:SUBSTANCE:97" name="hydroxypropyl methylcellulose" comment="" chebi-id="CHEBI:30618" relevant="false">hydroxypropyl methylcellulose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.149" epochem-id="EPOCHEM:NEW:COMPOUND:1318" name="magnesium aluminum silicate" comment="" chebi-id="WO2007041481:872179" relevant="false">magnesium aluminum silicate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.233" epochem-id="EPOCHEM:NEW:COMPOUND:25" name="propylene glycol" comment="CHEBI:16997" chebi-id="CHEBI:16997" relevant="false">propylene glycol</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.174" epochem-id="EPOCHEM:NEW:SUBSTANCE:109" name="propylene glycol alginate" comment="" chebi-id="WO2007041481:463637" relevant="false">propylene glycol alginate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.176" epochem-id="EPOCHEM:NEW:SUBSTANCE:61" name="sodium alginate" comment="" chebi-id="WO2007041481:110650" relevant="false">sodium alginate</ne>, white wax, xanthan gum, and yellow wax. In the preferred embodiment, the agent is <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.88" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> and the stabilizer may be a combination of one or more <ne id="WO2007041481.HC.class-names.57" epochem-id="EPOCHEM:NEW:CLASS:57" name="polysaccharides" comment="" chebi-id="CHEBI:18154" relevant="false" type="CLASS">polysaccharides</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.136" epochem-id="EPOCHEM:COMPOUND:1821" name="glycerol" comment="" chebi-id="CHEBI:17754" relevant="false">glycerol</ne>, <ne type="ONT" id="WO2007041481.HC.class-names.61" epochem-id="EPOCHEM:NEW:CLASS:303" name="bacteriostatic agents" comment="" chebi-id="WO2007041481:637969" relevant="false">bacteriostatic agents</ne>, <ne type="ONT" id="WO2007041481.HC.class-names.59" epochem-id="EPOCHEM:NEW:CLASS:18" name="isotonic agents" comment="" chebi-id="WO2007041481:439850" relevant="false">isotonic agents</ne>, <ne id="WO2007041481.HC.class-names.45" epochem-id="EPOCHEM:NEW:CLASS:70" name="lecithins" comment="" chebi-id="CHEBI:16110" relevant="false" type="CLASS">lecithins</ne>, or <ne type="ONT" id="WO2007041481.HC.class-names.54" epochem-id="EPOCHEM:NEW:CLASS:302" name="synthetic detergents" comment="" chebi-id="WO2007041481:151565" relevant="false">synthetic detergents</ne>. <ne type="ONT" id="WO2007041481.HC.class-names.86" epochem-id="EPOCHEM:NEW:CLASS:960" name="surfactants" comment="" chebi-id="CHEBI:35195" relevant="false">Surfactants</ne> Surfactants may be anionic, cationic, amphoteric or nonionic surface active agents. Suitable <ne type="ONT" id="WO2007041481.HC.class-names.81" epochem-id="EPOCHEM:NEW:CLASS:382" name="anionic surfactants" comment="" chebi-id="WO2007041481:606555" relevant="false">anionic surfactants</ne> include, but are not limited to, those containing <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.176" epochem-id="EPOCHEM:NEW:COMPOUND:1323" name="carboxylate" comment="" chebi-id="CHEBI:35757" relevant="false">carboxylate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.254" epochem-id="EPOCHEM:COMPOUND:1260" name="sulfonate" comment="" chebi-id="CHEBI:33543" relevant="false">sulfonate</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.184" epochem-id="EPOCHEM:COMPOUND:1225" name="sulfate" comment="" chebi-id="CHEBI:16189" relevant="false">sulfate</ne> ions.
Examples of <ne type="ONT" id="WO2007041481.HC.class-names.82" epochem-id="EPOCHEM:NEW:CLASS:382" name="anionic surfactants" comment="" chebi-id="WO2007041481:606555" relevant="false">anionic surfactants</ne> include <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.264" epochem-id="EPOCHEM:COMPOUND:7085" name="sodium" comment="" chebi-id="CHEBI:26708" relevant="false">sodium</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.204" epochem-id="EPOCHEM:COMPOUND:7084" name="potassium" comment="" chebi-id="CHEBI:26216" relevant="false">potassium</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.205" epochem-id="EPOCHEM:COMPOUND:4221" name="ammonium" comment="" chebi-id="CHEBI:28938" relevant="false">ammonium</ne> of long chain <ne id="WO2007041481.HC.class-names.63" epochem-id="EPOCHEM:NEW:CLASS:305" name="alkyl sulfonates" comment="" chebi-id="WO2007041481:987471" relevant="false" type="CLASS">alkyl sulfonates</ne> and <ne id="WO2007041481.HC.class-names.62" epochem-id="EPOCHEM:NEW:CLASS:304" name="alkyl aryl sulfonates" comment="" chebi-id="WO2007041481:933225" relevant="false" type="CLASS">alkyl aryl sulfonates</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.209" epochem-id="EPOCHEM:NEW:COMPOUND:1325" name="sodium dodecylbenzene sulfonate" comment="" chebi-id="WO2007041481:798925" relevant="false">sodium dodecylbenzene sulfonate</ne>; <ne id="WO2007041481.HC.class-names.64" epochem-id="EPOCHEM:NEW:CLASS:306" name="dialkyl sodium sulfosuccinates" comment="" chebi-id="WO2007041481:999941" relevant="false" type="CLASS">dialkyl sodium sulfosuccinates</ne>, such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.210" epochem-id="EPOCHEM:NEW:COMPOUND:1325" name="sodium dodecylbenzene sulfonate" comment="" chebi-id="WO2007041481:798925" relevant="false">sodium dodecylbenzene sulfonate</ne>; <ne id="WO2007041481.HC.class-names.65" epochem-id="EPOCHEM:NEW:CLASS:306" name="dialkyl sodium sulfosuccinates" comment="" chebi-id="WO2007041481:999941" relevant="false" type="CLASS">dialkyl sodium sulfosuccinates</ne>, such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.208" epochem-id="EPOCHEM:NEW:COMPOUND:1324" name="sodium bis-(2- ethylthioxyl)-sulfosuccinate" comment="" chebi-id="WO2007041481:816344" relevant="false">sodium bis-(2- ethylthioxyl)-sulfosuccinate</ne>; and <ne id="WO2007041481.HC.class-names.66" epochem-id="EPOCHEM:NEW:CLASS:307" name="alkyl sulfates" comment="" chebi-id="CHEBI:29281" relevant="false" type="CLASS">alkyl sulfates</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.164" epochem-id="EPOCHEM:NEW:COMPOUND:425" name="sodium lauryl sulfate" comment="" chebi-id="CHEBI:8984" relevant="false">sodium lauryl sulfate</ne>. Cationic <ne type="ONT" id="WO2007041481.HC.class-names.89" epochem-id="EPOCHEM:NEW:CLASS:960" name="surfactants" comment="" chebi-id="CHEBI:35195" relevant="false">surfactants</ne> include, but are not limited to, quaternary <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.206" epochem-id="EPOCHEM:COMPOUND:4221" name="ammonium" comment="" chebi-id="CHEBI:28938" relevant="false">ammonium</ne> compounds such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.212" epochem-id="EPOCHEM:NEW:COMPOUND:871" name="benzalkonium chloride" comment="" chebi-id="WO2007041481:455640" relevant="false">benzalkonium chloride</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.213" epochem-id="EPOCHEM:NEW:COMPOUND:872" name="benzethonium chloride" comment="" chebi-id="WO2007041481:277130" relevant="false">benzethonium chloride</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.211" epochem-id="EPOCHEM:NEW:COMPOUND:1326" name="cetrimonium bromide" comment="" chebi-id="CHEBI:3567" relevant="false">cetrimonium bromide</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.215" epochem-id="EPOCHEM:NEW:COMPOUND:1328" name="stearyl dimethylbenzyl ammonium chloride" comment="" chebi-id="WO2007041481:617971" relevant="false">stearyl dimethylbenzyl ammonium chloride</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.254" epochem-id="EPOCHEM:NEW:SUBSTANCE:54" name="polyoxyethylene" comment="" chebi-id="WO2007041481:310961" relevant="false">polyoxyethylene</ne> and coconut amine. Examples of nonionic <ne type="ONT" id="WO2007041481.HC.class-names.90" epochem-id="EPOCHEM:NEW:CLASS:960" name="surfactants" comment="" chebi-id="CHEBI:35195" relevant="false">surfactants</ne> include <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.273" epochem-id="EPOCHEM:NEW:COMPOUND:2088" name="ethylene glycol monostearate" comment="" chebi-id="WO2007041481:708617" relevant="false">ethylene glycol monostearate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.217" epochem-id="EPOCHEM:NEW:COMPOUND:1330" name="propylene glycol myristate" comment="" chebi-id="WO2007041481:201384" relevant="false">propylene glycol myristate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.148" epochem-id="EPOCHEM:NEW:COMPOUND:1028" name="glyceryl monostearate" comment="" chebi-id="WO2007041481:311712" relevant="false">glyceryl monostearate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.218" epochem-id="EPOCHEM:NEW:COMPOUND:1331" name="glyceryl stearate" comment="" chebi-id="WO2007041481:285243" relevant="false">glyceryl stearate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.219" epochem-id="EPOCHEM:NEW:COMPOUND:1332" name="polyglyceryl-4-oleate" comment="" chebi-id="WO2007041481:297718" relevant="false">polyglyceryl-4-oleate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.220" epochem-id="EPOCHEM:NEW:COMPOUND:1333" name="sorbitan acylate" comment="" chebi-id="WO2007041481:164357" relevant="false">sorbitan acylate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.75" epochem-id="EPOCHEM:COMPOUND:1888" name="sucrose" comment="" chebi-id="CHEBI:17992" relevant="false">sucrose</ne> acylate, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.147" epochem-id="EPOCHEM:NEW:SUBSTANCE:103" name="PEG" comment="" chebi-id="CHEBI:46793" relevant="false">PEG</ne>-150 laurate, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.148" epochem-id="EPOCHEM:NEW:SUBSTANCE:103" name="PEG" comment="" chebi-id="CHEBI:46793" relevant="false">PEG</ne>-400 monolaurate, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.238" epochem-id="EPOCHEM:NEW:SUBSTANCE:248" name="polyoxyethylene monolaurate" comment="" chebi-id="WO2007041481:58872" relevant="false">polyoxyethylene monolaurate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.260" epochem-id="EPOCHEM:NEW:SUBSTANCE:152" name="polysorbates" comment="" chebi-id="WO2007041481:981207" relevant="false">polysorbates</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.239" epochem-id="EPOCHEM:NEW:SUBSTANCE:249" name="polyoxyethylene octylphenylether" comment="" chebi-id="WO2007041481:236238" relevant="false">polyoxyethylene octylphenylether</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.149" epochem-id="EPOCHEM:NEW:SUBSTANCE:103" name="PEG" comment="" chebi-id="CHEBI:46793" relevant="false">PEG</ne>-1000 cetyl ether, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.240" epochem-id="EPOCHEM:NEW:SUBSTANCE:250" name="polyoxyethylene tridecyl ether" comment="" chebi-id="WO2007041481:931820" relevant="false">polyoxyethylene tridecyl ether</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.261" epochem-id="EPOCHEM:NEW:SUBSTANCE:314" name="polypropylene glycol butyl ether" comment="" chebi-id="WO2007041481:851251" relevant="false">polypropylene glycol butyl ether</ne>, Poloxamer&lt;(R)&gt; 401 , <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.232" epochem-id="EPOCHEM:NEW:COMPOUND:2000" name="stearoyl monoisopropanolamide" comment="" chebi-id="WO2007041481:430214" relevant="false">stearoyl monoisopropanolamide</ne>, and <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.258" epochem-id="EPOCHEM:NEW:SUBSTANCE:54" name="polyoxyethylene" comment="" chebi-id="WO2007041481:310961" relevant="false">polyoxyethylene</ne> hydrogenated tallow amide. Examples of <ne type="ONT" id="WO2007041481.HC.class-names.67" epochem-id="EPOCHEM:NEW:CLASS:308" name="amphoteric surfactants" comment="" chebi-id="WO2007041481:648889" relevant="false">amphoteric surfactants</ne> include <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.221" epochem-id="EPOCHEM:NEW:COMPOUND:1334" name="sodium N-dodecyl-[beta]-alanine" comment="" chebi-id="WO2007041481:591190" relevant="false">sodium N-dodecyl-[beta]-alanine</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.222" epochem-id="EPOCHEM:NEW:COMPOUND:1335" name="sodium N-lauryl-[beta]-iminodipropionate" comment="" chebi-id="WO2007041481:464981" relevant="false">sodium N-lauryl-[beta]-iminodipropionate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.223" epochem-id="EPOCHEM:NEW:COMPOUND:1336" name="myristoamphoacetate" comment="" chebi-id="WO2007041481:901801" relevant="false">myristoamphoacetate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.224" epochem-id="EPOCHEM:NEW:COMPOUND:1337" name="lauryl betaine" comment="" chebi-id="WO2007041481:270143" relevant="false">lauryl betaine</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.225" epochem-id="EPOCHEM:NEW:COMPOUND:1338" name="lauryl sulfobetaine" comment="" chebi-id="WO2007041481:554779" relevant="false">lauryl sulfobetaine</ne>.
If desired, the tablets, wafers, films, lozenges, beads, granules, or particles may also contain minor amount of nontoxic auxiliary substances such as dyes, sweeteners, coloring and flavoring agents, pH buffering agents, or preservatives.
<ne id="WO2007041481.HC.class-names.124" epochem-id="EPOCHEM:NEW:CLASS:1079" name="polymers" comment="" chebi-id="CHEBI:33839" relevant="false" type="CLASS">Polymers</ne> Blending or copolymerization sufficient to provide a certain amount of hydrophilic character can be useful to improve wettability of the materials. For example, about 5% to about 20% of monomers may be hydrophilic monomers. Hydrophilic <ne id="WO2007041481.HC.class-names.125" epochem-id="EPOCHEM:NEW:CLASS:1079" name="polymers" comment="" chebi-id="CHEBI:33839" relevant="false" type="CLASS">polymers</ne> such as <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.265" epochem-id="EPOCHEM:NEW:SUBSTANCE:316" name="hydroxylpropylcellulose" comment="" chebi-id="WO2007041481:987132" relevant="false">hydroxylpropylcellulose</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.substance-names.266" epochem-id="EPOCHEM:NEW:SUBSTANCE:317" name="HPC" comment="" chebi-id="WO2007041481:841967" relevant="false">HPC</ne>), <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.222" epochem-id="EPOCHEM:NEW:SUBSTANCE:120" name="hydroxpropylmethylcellulose" comment="" chebi-id="WO2007041481:492156" relevant="false">hydroxpropylmethylcellulose</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.substance-names.262" epochem-id="EPOCHEM:NEW:SUBSTANCE:304" name="HPMC" comment="" chebi-id="WO2007041481:268267" relevant="false">HPMC</ne>), <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.200" epochem-id="EPOCHEM:NEW:SUBSTANCE:87" name="carboxymethylcellulose" comment="" chebi-id="WO2007041481:784292" relevant="false">carboxymethylcellulose</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.substance-names.264" epochem-id="EPOCHEM:NEW:SUBSTANCE:315" name="CMC" comment="" chebi-id="WO2007041481:352358" relevant="false">CMC</ne>) are commonly used for this purpose. Also suitable are <ne id="WO2007041481.HC.class-names.118" epochem-id="EPOCHEM:NEW:CLASS:1076" name="hydrophobic polymers" comment="" chebi-id="WO2007041481:512344" relevant="false" type="CLASS">hydrophobic polymers</ne> such as <ne id="WO2007041481.HC.class-names.116" epochem-id="EPOCHEM:NEW:CLASS:140" name="polyesters" comment="" chebi-id="CHEBI:26178" relevant="false" type="CLASS">polyesters</ne> and <ne id="WO2007041481.HC.class-names.117" epochem-id="EPOCHEM:NEW:CLASS:274" name="polyimides" comment="" chebi-id="WO2007041481:365732" relevant="false" type="CLASS">polyimides</ne>. It is known to those skilled in the art that these <ne id="WO2007041481.HC.class-names.127" epochem-id="EPOCHEM:NEW:CLASS:1079" name="polymers" comment="" chebi-id="CHEBI:33839" relevant="false" type="CLASS">polymers</ne> may be blended with <ne id="WO2007041481.HC.class-names.119" epochem-id="EPOCHEM:NEW:CLASS:1077" name="polyanhydrides" comment="" chebi-id="WO2007041481:994802" relevant="false" type="CLASS">polyanhydrides</ne> to achieve compositions with different drug release profiles and mechanical strengths. Preferably, the <ne id="WO2007041481.HC.class-names.128" epochem-id="EPOCHEM:NEW:CLASS:1079" name="polymers" comment="" chebi-id="CHEBI:33839" relevant="false" type="CLASS">polymers</ne> are bioerodable, with preferred molecular weights ranging from 1000 to 15,000 Da, and most preferably 2000 to 5000 Da.
Film
The composition may be in the form of a film. The film is a clear or opaque, flexible, thin material. Typical thicknesses range from 0.01 to 2mm. The film may have any suitable shape, including round, oval, rectangle, or square. The film may be a monolayer, bilayer or trilayer film. In the preferred embodiment, the film is designed to be suitable for sublingual administration. The monolayer film contains an active agent and one or more excipients.
The bilayer film contains one or more excipients, such as a <ne type="ONT" id="WO2007041481.HC.class-names.30" epochem-id="EPOCHEM:NEW:CLASS:292" name="solubilizing agent" comment="" chebi-id="WO2007041481:514080" relevant="false">solubilizing agent</ne> and/or a metal <ne type="ONT" id="WO2007041481.HC.class-names.13" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne>, in a first layer, and an active agent in the second layer. This configuration allows the active agent to be stored separated from the excipients, and may increase the stability of the active agent, and optionally increases the shelf life of the composition compared to if the excipients and active agent were contained in a single layer. The trilayer film contains three layers of film. Each of the layers may be different, or two of the layers, such as the bottom and top layers, may have substantially the same composition. In one embodiment, the bottom and top layers surround a core layer containing the active agent. The bottom and top layers may contain one or more excipients, such as a <ne type="ONT" id="WO2007041481.HC.class-names.31" epochem-id="EPOCHEM:NEW:CLASS:292" name="solubilizing agent" comment="" chebi-id="WO2007041481:514080" relevant="false">solubilizing agent</ne> and a metal <ne type="ONT" id="WO2007041481.HC.class-names.14" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne>. Perferably the bottom and top layers have the same composition. Alternatively, the bottom and top layers may contain different excipient(s), or different amounts of the same excipient(s). The core layer typically contains the active agent, optionally with one or more excipients. In the preferred embodiment, the film is a bilayer film that contains
<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.52" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.27" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne> in one layer and <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.89" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> in the second layer. Each layer may contain additional excipients, such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.132" epochem-id="EPOCHEM:NEW:COMPOUND:98" name="glycerin" comment="" chebi-id="CHEBI:17754" relevant="false">glycerin</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.161" epochem-id="EPOCHEM:NEW:SUBSTANCE:4" name="polyvinyl alcohol" comment="" chebi-id="CHEBI:17246" relevant="false">polyvinyl alcohol</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.160" epochem-id="EPOCHEM:NEW:SUBSTANCE:75" name="carboxymethyl cellulose" comment="" chebi-id="WO2007041481:984331" relevant="false">carboxymethyl cellulose</ne>, and optionally <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.150" epochem-id="EPOCHEM:NEW:SUBSTANCE:103" name="PEG" comment="" chebi-id="CHEBI:46793" relevant="false">PEG</ne> (such as <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.145" epochem-id="EPOCHEM:NEW:SUBSTANCE:101" name="PEG 400" comment="" chebi-id="WO2007041481:36900" relevant="false">PEG 400</ne> or <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.146" epochem-id="EPOCHEM:NEW:SUBSTANCE:102" name="PEG 1600" comment="" chebi-id="WO2007041481:468782" relevant="false">PEG 1600</ne>). In one embodiment, a third layer can be located between the active agent layer and the layer containing the other ingredients to further protect the active agent from degradative ingredients located in the other layer during storage. Suitable materials for the protective layer include <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.144" epochem-id="EPOCHEM:NEW:SUBSTANCE:100" name="carboxymethylcellulose sodium" comment="" chebi-id="WO2007041481:710841" relevant="false">carboxymethylcellulose sodium</ne>, carnauba wax, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.141" epochem-id="EPOCHEM:NEW:SUBSTANCE:99" name="cellulose acetate phthalate" comment="" chebi-id="WO2007041481:808653" relevant="false">cellulose acetate phthalate</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.133" epochem-id="EPOCHEM:NEW:COMPOUND:246" name="cetyl alcohol" comment="" chebi-id="CHEBI:16125" relevant="false">cetyl alcohol</ne>, confectioner's sugar, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.140" epochem-id="EPOCHEM:NEW:SUBSTANCE:98" name="ethylcellulose" comment="" chebi-id="WO2007041481:335383" relevant="false">ethylcellulose</ne>, gelatin, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.134" epochem-id="EPOCHEM:NEW:SUBSTANCE:57" name="hydroxyethyl cellulose" comment="" chebi-id="WO2007041481:750713" relevant="false">hydroxyethyl cellulose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.133" epochem-id="EPOCHEM:NEW:SUBSTANCE:97" name="hydroxypropyl methylcellulose" comment="" chebi-id="CHEBI:30618" relevant="false">hydroxypropyl methylcellulose</ne>, liquid <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.95" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.80" epochem-id="EPOCHEM:NEW:COMPOUND:1310" name="maltodextrin" comment="" chebi-id="WO2007041481:45063" relevant="false">maltodextrin</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.138" epochem-id="EPOCHEM:NEW:SUBSTANCE:56" name="methylcellulose" comment="" chebi-id="WO2007041481:399316" relevant="false">methylcellulose</ne>, microcrystalline wax, <ne id="WO2007041481.HC.class-names.41" epochem-id="EPOCHEM:NEW:CLASS:294" name="polymethacrylates" comment="" chebi-id="WO2007041481:620606" relevant="true" type="CLASS">polymethacrylates</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.162" epochem-id="EPOCHEM:NEW:SUBSTANCE:4" name="polyvinyl alcohol" comment="" chebi-id="CHEBI:17246" relevant="false">polyvinyl alcohol</ne>, shellac, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.76" epochem-id="EPOCHEM:COMPOUND:1888" name="sucrose" comment="" chebi-id="CHEBI:17992" relevant="false">sucrose</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.252" epochem-id="EPOCHEM:NEW:SUBSTANCE:313" name="talc" comment="" chebi-id="WO2007041481:714483" relevant="false">talc</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.77" epochem-id="EPOCHEM:COMPOUND:7651" name="titanium dioxide" comment="" chebi-id="CHEBI:32234" relevant="false">titanium dioxide</ne>, and zein.
By altering the composition of the excipients, the film can be designed to dissolve rapidly (less than 30 seconds) or slowly (up to 15 minutes) in order to achieve the desired absorption profile and subsequent effect. The film may dissolve in a time period ranging from 3 to 5 minutes, 5 to 8 minutes, or 8 to 12 minutes. Preferably, the film dissolves in a time period ranging from 15 seconds to 2 minutes.
Lozenge, Tablet, Capsule, or Wafer
In another embodiment, the composition is in the form of a lozenge, tablet, capsule, or wafer containing the active agent and one or more excipients, such as <ne type="ONT" id="WO2007041481.HC.class-names.70" epochem-id="EPOCHEM:NEW:CLASS:33" name="chelators" comment="" chebi-id="CHEBI:38161" relevant="false">chelators</ne>, stabilizing agents, solubilizing agents.
Lozenge
The lozenge core is composed of a solid gel or a lyophilized wafer, containing an active agent in the core. Optionally, the core also contains a stabilizing agent, optionally with one or more additional excipients. Optionally, the upper and lower surfaces of the lozenge core are coated with a <ne type="ONT" id="WO2007041481.HC.class-names.15" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne>, such as <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.271" epochem-id="EPOCHEM:COMPOUND:7085" name="sodium" comment="" chebi-id="CHEBI:26708" relevant="false">sodium</ne> <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.53" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne>. Alternatively, the <ne type="ONT" id="WO2007041481.HC.class-names.16" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> may be mixed with the active agent in the core. In the preferred embodiment, the core contains <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.190" epochem-id="EPOCHEM:NEW:SUBSTANCE:12" name="alginate" comment="" chebi-id="WO2007041481:806723" relevant="false">alginate</ne> (preferably <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.114" epochem-id="EPOCHEM:COMPOUND:7090" name="calcium" comment="" chebi-id="CHEBI:22984" relevant="false">calcium</ne> stabilized <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.191" epochem-id="EPOCHEM:NEW:SUBSTANCE:12" name="alginate" comment="" chebi-id="WO2007041481:806723" relevant="false">alginate</ne>), <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.28" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.54" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne>, and <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.90" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>. The lozenge covers a large surface area with a thin layer, and can be made in any convenient shape. Typically it has a round or oval shape. Generally, the lozenge has a diameter and thickness that is approximately the same as the diameter and thickness of a dime. In one embodiment, the lozenge contains <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.235" epochem-id="EPOCHEM:NEW:COMPOUND:875" name="glycerine" comment="" chebi-id="CHEBI:17754" relevant="false">glycerine</ne>.
Tablet In one embodiment, the tablet is a compressed homogenous powder of all of the ingredients. In another embodiment, inactive ingredients, such as the filler and binding agent, and one or more excipients, including the solubilizing agents, are formed into one tablet. The active agent along with filler, binding agent, and other excipients are formed into another tablet. Then the two tablets are placed together and coated to form a single tablet. Optionally, the tablet is coated with an enteric coating. Wafer
The composition may be in the form of a wafer. The wafer is a flat, solid dosage form. Typical thicknesses range from 0.1mm to 1.5cm. Typical diameters range from 0.2 to 5cm. The wafer may be in any suitable shape, including round, oval, rectangular, or square. The wafer may be a monolayer, bilayer or trilayer. In the preferred embodiment, the wafer is designed to be suitable for sublingual administration. The monolayer wafer contains an active agent and one or more excipients. The bilayer wafer contains one or more excipients, such as a <ne type="ONT" id="WO2007041481.HC.class-names.32" epochem-id="EPOCHEM:NEW:CLASS:292" name="solubilizing agent" comment="" chebi-id="WO2007041481:514080" relevant="false">solubilizing agent</ne> and/or a metal <ne type="ONT" id="WO2007041481.HC.class-names.17" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne>, in a first layer and an active agent in the second layer.
This configuration allows the active agent to be stored separated from the excipients, and may increase the stability of the active agent, and optionally increases the shelf life of the composition compared to if the excipients and active agent were contained in a single layer. The trilayer wafer contains three layers. Each of the layers may be different, or two of the layers, such as the bottom and top layers may have substantially the same composition. In one embodiment, the bottom and top layers surround a core layer containing the active agent. The bottom and top layers may contain one or more excipients, such as a <ne type="ONT" id="WO2007041481.HC.class-names.33" epochem-id="EPOCHEM:NEW:CLASS:292" name="solubilizing agent" comment="" chebi-id="WO2007041481:514080" relevant="false">solubilizing agent</ne> and a metal <ne type="ONT" id="WO2007041481.HC.class-names.18" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne>. Preferably the bottom and top layers have the same composition. Alternatively, the bottom and top layers may contain different excipient(s), or different amounts of the same excipient(s). The core layer typically contains the active agent, optionally with one or more excipients.
Capsules Another suitable dosage form is a capsule. The capsule contains a rapidly dissolving outer shell, which is typically composed of <ne id="WO2007041481.HC.class-names.75" epochem-id="EPOCHEM:NEW:CLASS:17" name="sugars" comment="" chebi-id="WO2007041481:254249" relevant="false" type="CLASS">sugars</ne>, <ne id="WO2007041481.HC.class-names.121" epochem-id="EPOCHEM:NEW:CLASS:1078" name="starches" comment="" chebi-id="WO2007041481:326511" relevant="false" type="CLASS">starches</ne>, <ne id="WO2007041481.HC.class-names.129" epochem-id="EPOCHEM:NEW:CLASS:1079" name="polymers" comment="" chebi-id="CHEBI:33839" relevant="false" type="CLASS">polymers</ne> (and other suitable pharmaceutical materials). The capsule contains powders or granules of agent and excipient. The capsule is designed rapidly release powders or small rapidly dissolving granules into the oral cavity following administration.
Examples
The present invention will be further understood by reference to the following non-limiting examples.
The following definitions are used in the examples and figures: T, time D, day Min, minutes C, concentration
Cmax, maximum concentration in plasma tcmax, time to maximal concentration tmax, time to maximal activity GIRmax t+- 50%, time to half-maximal activity before and after GIRma[chi] GIR3 <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.96" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> infusion rate
GIRmax, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.97" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> infusion rate maximal activity TGiRmax, time to maximal activity GIRmax TGiRmaX5 time to maximal activity GIRmax TGIR+-50%, time to half-maximal activity before and after GIRmax AUC, area under the curve
The following <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.248" epochem-id="EPOCHEM:NEW:SUBSTANCE:312" name="insulins" comment="" chebi-id="WO2007041481:619937" relevant="false">insulins</ne> were used for the studies described herein. <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.163" epochem-id="EPOCHEM:NEW:SUBSTANCE:105" name="Human insulin" comment="" chebi-id="WO2007041481:962261" relevant="false">Human insulin</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.129" epochem-id="EPOCHEM:NEW:SUBSTANCE:95" name="HUMALIN" comment="" chebi-id="WO2007041481:634619" relevant="false">HUMALIN</ne>(R) R, U 100, solution for injection from Eli Lilly and Company, single dose 0.1 IU/kg
<ne type="CHEMICAL" id="WO2007041481.HC.substance-names.92" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> lispro, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.131" epochem-id="EPOCHEM:NEW:SUBSTANCE:96" name="HUMALO" comment="" chebi-id="WO2007041481:815870" relevant="false">HUMALO</ne> G(R) R, solution for injection, Eli LiIl and Company, single dose 0.1 IU/kg
<ne type="CHEMICAL" id="WO2007041481.HC.substance-names.93" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.156" epochem-id="EPOCHEM:NEW:SUBSTANCE:104" name="glargine" comment="" chebi-id="WO2007041481:668772" relevant="false">glargine</ne>, LANTUS(R) R, U 100, Sanofi-Aventis, solution for injection, 0.1 IU/kg
VIAJECT(TM), solution for injection 25 IU/ml prepared daily from recombinant human <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.94" epochem-id="EPOCHEM:NEW:SUBSTANCE:105" name="Human insulin" comment="" chebi-id="WO2007041481:962261" relevant="false">insulin</ne>, from Biodel Inc. The formulation is: <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.95" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne>, USP/NF 0.9 mg/ml
<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.68" epochem-id="EPOCHEM:NEW:COMPOUND:1308" name="Sodium phosphate" comment="" chebi-id="WO2007041481:466832" relevant="false">Sodium phosphate</ne> USP/NF, 0.7 mg/ml
<ne type="FORMULA" id="WO2007041481.HC.formula-names.1" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>, USP/NF appr. 7.1 mg/niL <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.29" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">Citric Acid</ne>, USP/NF 1.8 mg/ml
<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.72" epochem-id="EPOCHEM:NEW:COMPOUND:1309" name="Edetate Disodium" comment="" chebi-id="WO2007041481:620130" relevant="false">Edetate Disodium</ne>, EDTA5 USP/NF 1.8 mg/ml
<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.67" epochem-id="EPOCHEM:NEW:COMPOUND:1307" name="Meta-Cresol" comment="" chebi-id="CHEBI:17231" relevant="false">Meta-Cresol</ne> 3.0 mg/ml
<ne type="FORMULA" id="WO2007041481.HC.formula-names.4" epochem-id="EPOCHEM:NEW:FORMULA:106" name="HCl" comment="" chebi-id="CHEBI:17883" relevant="false">HCl</ne>/<ne type="FORMULA" id="WO2007041481.HC.formula-names.2" epochem-id="EPOCHEM:NEW:FORMULA:5" name="NaOH" comment="" chebi-id="CHEBI:32145" relevant="false">NaOH</ne> USP/NF pH buffer to pH 3.5 to 4.5 (3.95)
Sterile <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.71" epochem-id="EPOCHEM:NEW:COMPOUND:9" name="Water" comment="" chebi-id="CHEBI:15377" relevant="false">Water</ne>, USP/NF to 10 ml
Example 1: Comparison of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.96" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> size and absorption with and without <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.55" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne>/<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.30" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">Citric Acid</ne>. Materials and Meth ods
VIAJECT(TM) diluent was added to <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.166" epochem-id="EPOCHEM:NEW:SUBSTANCE:106" name="HUMALOG" comment="" chebi-id="WO2007041481:727145" relevant="false">HUMALOG</ne>(R) and <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.130" epochem-id="EPOCHEM:NEW:SUBSTANCE:95" name="HUMALIN" comment="" chebi-id="WO2007041481:634619" relevant="false">HUMALIN</ne>(R) 1 mg/ml solution in order to achieve a concentration of 0, 1, 2, 3, or 4 mg VIAJECT(TM) diluent/mL. 0.5 mL of the combined ingredients were added to the top of NANOSEP(R) microtubes and tubes were spun at 10,000 rpm for 10 minutes in a microcentrifuge (Fisher Scientific). <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.97" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne> was assayed before and after the spin, and the percent recovered in the filtrate was determined by dividing the amount of the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.98" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> that filtered through the filter by the initial quantity placed on top.
These were tested to determine apparent permeability as a function of time (minutes) over a period of one hour, and for effect on Tmax. Immortalized epithelial cell line cultures were seeded on transwell membranes.
When the cells were grown to confluence, at time zero, the fluid in the top chambers of the transwell plates was replaced with 0.5 ml of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.99" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> solution (i.e. solution 1 or solution 2). Two plates with solution 1, two plates with solution 2 and one plate with the control solution (no cells) were tested simultaneously. The lower chamber of each plate contained 1.5mL of saline solution. At each time point, lOO[mu]Lof fluid from the lower chamber was removed and analyzed with Enzyme-Linked Immunosorbent Assay (ELISA). lOO[mu]L of saline was added to the lower chamber to maintain a constant volume of 1.5 mL throughout the study. The amount of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.100" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> removed from the lower chamber at each time point was added to the amount removed in the previous time point(s) to determine the cumulative amount of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.101" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> recovered in the lower chamber.
Results
As shown in Figures 1 (molecular weight) and 2 (apparent permeability), adding VIAJECT(TM) (<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.56" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne> and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.31" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>) to <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.102" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> results in two populations of molecules, a small size population of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.103" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> molecules and a large size population of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.104" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> molecules. Addition of more <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.57" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne> (i.e., a greater amount of VIAJECT(TM)) increases the size of the mean <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.105" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> diameter, demonstrating that mean diameter is concentration dependent. The <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.58" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne> chelates <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.105" epochem-id="EPOCHEM:COMPOUND:7669" name="zinc" comment="" chebi-id="CHEBI:27363" relevant="false">zinc</ne> and charge masks the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.106" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>, which further promotes its absorption across the epithelium, as shown in Figure 2 as a function of apparent permeability.
As demonstrated by the data for injected <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.107" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> shown in Table 1 below, absorption of the VIAJECT(TM) is so fast that the concentration of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.108" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> in the blood over time resembles the natural initial <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.109" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> spike produced by non-diabetic individuals at the beginning of a meal. Table 1: Effect of <ne type="ONT" id="WO2007041481.HC.class-names.19" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">Chelator</ne>/<ne id="WO2007041481.HC.class-names.106" epochem-id="EPOCHEM:NEW:CLASS:1073" name="acid" comment="" chebi-id="CHEBI:37527" relevant="false" type="CLASS">Acid</ne> on Traax.
</P>
<P>[0079]
EMI21.1
Example 2: Co-administration compared to Administration of Rapid and Long-Lasting <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.110" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">Insulin</ne>
Materials and Methods
In this study, patients with type 1 diabetes mellitus were treated with either: 1) an injection of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.111" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.157" epochem-id="EPOCHEM:NEW:SUBSTANCE:104" name="glargine" comment="" chebi-id="WO2007041481:668772" relevant="false">glargine</ne> at a dose equivalent to the subject's usual daily dose of basal <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.112" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> AND a separate injection of VIAJECT(TM); or
</P>
<P>2) an injection of <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.113" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.158" epochem-id="EPOCHEM:NEW:SUBSTANCE:104" name="glargine" comment="" chebi-id="WO2007041481:668772" relevant="false">glargine</ne> at a dose equivalent to the subject's usual daily dose of basal <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.114" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> mixed with VIAJECT(TM).
Results
The results are shown in Figures 3 and 4. Figure 3 is a graph of blood <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.98" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne> (mg/dl) during baseline, at the time of a meal, and following the meal, for the separate injections of LANTUS(R) and VIAJECT(TM) as compared to injection of the mixture. Figure 4 is a graph of the area under the curves at 60,120, 180, 240, 300, 360, 420, and 480 minutes.
For the first four hours after administration, there is no significant difference between LANTUS(R) and VIAJECT(TM) mixed together or administered separately, however, after the first four hours and up to at least eight hours, there is a very large and significant difference with the mixture, as compared to the separate injections, of VIAJECT(TM) and LANTUS(R) having a much greater effect on lowering blood <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.99" epochem-id="EPOCHEM:COMPOUND:2079" name="glucose" comment="" chebi-id="CHEBI:17234" relevant="false">glucose</ne>. The overall significance of this is PO.0004
LANTUS t-test
</P>
<P>[0088]
EMI22.1
These results indicate that the <ne type="ONT" id="WO2007041481.HC.class-names.20" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> in the mixture effects the biopharmacokinetics .
We claim:
</P>
<P>1. A formulation comprising <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.115" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> selected from the group consisting of intermediate acting, and long acting <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.116" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> with an effective amount of a <ne type="ONT" id="WO2007041481.HC.class-names.21" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> and an <ne type="ONT" id="WO2007041481.HC.class-names.98" epochem-id="EPOCHEM:NEW:CLASS:1072" name="acidifying agent" comment="" chebi-id="WO2007041481:823849" relevant="false">acidifying agent</ne> to enhance the rate or amount of uptake by a patient.
</P>
<P>2. The formulation of claim 1 further comprising a rapid acting <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.117" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne>.
</P>
<P>3. The formulation of claim 1, wherein the <ne type="ONT" id="WO2007041481.HC.class-names.22" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> is selected from the group consisting of <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.3" epochem-id="EPOCHEM:NEW:COMPOUND:1299" name="ethylenediaminetetraacetic acid" comment="" chebi-id="CHEBI:42191" relevant="true">ethylenediaminetetraacetic acid</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.59" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne>), <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.6" epochem-id="EPOCHEM:NEW:COMPOUND:1300" name="dimercaprol" comment="" chebi-id="WO2007041481:771195" relevant="true">dimercaprol</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.62" epochem-id="EPOCHEM:NEW:COMPOUND:1304" name="BAL" comment="" chebi-id="WO2007041481:19869" relevant="false">BAL</ne>), <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.8" epochem-id="EPOCHEM:NEW:COMPOUND:1301" name="penicillamine" comment="" chebi-id="WO2007041481:759765" relevant="false">penicillamine</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.127" epochem-id="EPOCHEM:NEW:SUBSTANCE:39" name="alginic acid" comment="" chebi-id="WO2007041481:389621" relevant="false">alginic acid</ne>, Chlorella, Cilantro, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.227" epochem-id="EPOCHEM:NEW:COMPOUND:1997" name="alpha lipoic acid" comment="" chebi-id="WO2007041481:775873" relevant="false">Alpha Lipoic Acid</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.37" epochem-id="EPOCHEM:NEW:COMPOUND:1302" name="Dimercaptosuccinic Acid" comment="" chebi-id="WO2007041481:192235" relevant="true">Dimercaptosuccinic Acid</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.66" epochem-id="EPOCHEM:NEW:COMPOUND:1306" name="DMSA" comment="" chebi-id="WO2007041481:112811" relevant="false">DMSA</ne>), <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.39" epochem-id="EPOCHEM:NEW:COMPOUND:1303" name="dimercaptopropane sulfonate" comment="" chebi-id="WO2007041481:77436" relevant="true">dimercaptopropane sulfonate</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.64" epochem-id="EPOCHEM:NEW:COMPOUND:1305" name="DMPS" comment="" chebi-id="CHEBI:888" relevant="false">DMPS</ne>), and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.41" epochem-id="EPOCHEM:COMPOUND:441" name="oxalic acid" comment="" chebi-id="CHEBI:16995" relevant="true">oxalic acid</ne>.
</P>
<P>4. The formulation of claim 3, wherein the <ne type="ONT" id="WO2007041481.HC.class-names.23" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> is <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.4" epochem-id="EPOCHEM:NEW:COMPOUND:1299" name="ethylenediaminetetraacetic acid" comment="" chebi-id="CHEBI:42191" relevant="true">ethylenediaminetetraacetic acid</ne> (<ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.60" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007041481:692225" relevant="false">EDTA</ne>).
</P>
<P>5. The formulation of claim 1, wherein the agent is a charged compound and wherein the <ne type="ONT" id="WO2007041481.HC.class-names.24" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> and <ne type="ONT" id="WO2007041481.HC.class-names.34" epochem-id="EPOCHEM:NEW:CLASS:292" name="solubilizing agent" comment="" chebi-id="WO2007041481:514080" relevant="false">solubilizing agent</ne> are present in effective amounts to mask charges on the agent.
</P>
<P>6. The formulation of claim 1 wherein the <ne type="ONT" id="WO2007041481.HC.class-names.35" epochem-id="EPOCHEM:NEW:CLASS:292" name="solubilizing agent" comment="" chebi-id="WO2007041481:514080" relevant="false">solubilizing agent</ne> is an <ne id="WO2007041481.HC.class-names.107" epochem-id="EPOCHEM:NEW:CLASS:1073" name="acid" comment="" chebi-id="CHEBI:37527" relevant="false" type="CLASS">acid</ne> selected from the group consisting of <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.11" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.14" epochem-id="EPOCHEM:NEW:COMPOUND:963" name="ascorbic acid" comment="" chebi-id="CHEBI:22652" relevant="false">ascorbic acid</ne>, <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.32" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>, and <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.35" epochem-id="EPOCHEM:NEW:COMPOUND:395" name="hydrochloric acid" comment="" chebi-id="CHEBI:17883" relevant="false">hydrochloric acid</ne>.
</P>
<P>7. The formulation of claim 6 wherein the <ne type="ONT" id="WO2007041481.HC.class-names.36" epochem-id="EPOCHEM:NEW:CLASS:292" name="solubilizing agent" comment="" chebi-id="WO2007041481:514080" relevant="false">solubilizing agent</ne> is <ne type="CHEMICAL" id="WO2007041481.HC.chemical-names.33" epochem-id="EPOCHEM:COMPOUND:963" name="citric acid" comment="" chebi-id="CHEBI:30769" relevant="false">citric acid</ne>.
</P>
<P>8. The formulation of claim 1, wherein the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.118" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> is natural or recombinant human <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.119" epochem-id="EPOCHEM:NEW:SUBSTANCE:105" name="Human insulin" comment="" chebi-id="WO2007041481:962261" relevant="false">insulin</ne>.
</P>
<P>9. The formulation of claim 1 or 2 in a solid formulation for administration to a mucosal surface.
</P>
<P>10. The formulation of claim 1 or 2 in a formulation for administration by injection.
</P>
<P>11. A formulation suitable for pulmonary administration of an <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.120" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> in combination with an effective amount of a <ne type="ONT" id="WO2007041481.HC.class-names.25" epochem-id="EPOCHEM:NEW:CLASS:291" name="chelator" comment="" chebi-id="CHEBI:38161" relevant="true">chelator</ne> and an <ne type="ONT" id="WO2007041481.HC.class-names.99" epochem-id="EPOCHEM:NEW:CLASS:1072" name="acidifying agent" comment="" chebi-id="WO2007041481:823849" relevant="false">acidifying agent</ne> to enhance the rate or amount of uptake by a patient.
</P>
<P>12. The formulation of claim 11 wherein the <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.121" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> is a natural or recombinant <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.122" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> selected from the group consisting of rapid, intermediate and long acting <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.249" epochem-id="EPOCHEM:NEW:SUBSTANCE:312" name="insulins" comment="" chebi-id="WO2007041481:619937" relevant="false">insulins</ne>.
</P>
<P>13. A method of administering <ne type="CHEMICAL" id="WO2007041481.HC.substance-names.123" epochem-id="EPOCHEM:NEW:SUBSTANCE:94" name="insulin" comment="" chebi-id="WO2007041481:21079" relevant="false">insulin</ne> to a patient in need thereof comprising administering the formulation of any of claims 1-12 to the patient.
</P>
<P>14. The method of claim 13 wherein the formulation is administered to a mucosal surface selected from the group consisting of oral, sublingual, buccal, nasal, rectal, or vaginal.
</P>
<P>15. The method of claim 13 comprising administering the formulation of claim 10 or 11 to the pulmonary region of a patient.
</P>
<P>16. The method of claim 13 wherein the formulation of any of claims 1- 10 is administered by injection.
</P></DIV>
<DIV><P>
</P></DIV>
</BODY>
</PAPER>
